ClinicalTrials.gg
CompletedNCT03445065Updated Sep 10, 2021Results posted

A French Study to Evaluate the Usefulness of an Implantable Continuous Glucose Monitoring (CGM) Sensor to Improve Glycemic Control in Participants With Diabetes Mellitus

An interventional study of Eversense XL CGM System and Usual SMBG or FGM device used by participants in Diabetes Mellitus, sponsored by Hoffmann-La Roche. Completed at 20 sites in France. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2021-09-10.

Sponsored by Hoffmann-La Roche · Not applicable, Interventional, and Diagnostic

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
239
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 12 studies in Diabetes Mellitus by Hoffmann-La Roche — none open to participants now, none under way, none of them phase 3. Diabetes Mellitus · Hoffmann-La Roche.

Enrollment
4th of 10
239 · median 180
Started
2018
the only one that year
No phase
3 of 12
none open now
Registered
10th of 12
by date

Among the 12 studies in Diabetes Mellitus by Hoffmann-La Roche, this one is the 4th largest by enrollment of the 10 interventional ones that give a count, is the only one that started in 2018, is one of 3 with no phase, and was the 10th registered.

Diabetes Mellitus

8,294 studies on the registry are indexed under Diabetes Mellitus; 1,073 are open to participants now.

Browse Diabetes Mellitus studies →

Open to participants now

None of the 12 studies in Diabetes Mellitus by Hoffmann-La Roche is open now. The open studies under Diabetes Mellitus, anywhere →

Who these studies take

Of the 650 Diabetes Mellitus studies recruiting now, 359 (55%) set no upper age limit and 195 (30%) stop at 75 or younger; 89 take children under 18; 182 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Download CSVNarrow it in search →With an account: the 12 studies in Diabetes Mellitus by Hoffmann-La Roche as a file.
02

Study summary

This study will be conducted in France and will evaluate the usefulness of using a long-term subcutaneously inserted continuous glucose monitoring (CGM) sensor (the Eversense XL CGM System) to improve glycemic control in patients with either Type 1 or Type 2 diabetes mellitus under insulin therapy. Participants will be enrolled into one of two cohorts (Cohorts 1 and 2). Cohort 1 will be focused on participants with Type 1 or Type 2 diabetes with hemoglobin A1C (HbA1c) >8%. Cohort 2 will be focused on participants with Type 1 diabetes spending more than 1.5 hours per day with mean glucose \<70 mg/dL, including excursions below 54 mg/dL, for at least 28 days. Within each cohort, participants will be randomized in a 2:1 ratio to one of two groups: the Enabled and Control groups, respectively. The Enabled group will be trained to use the CGM system, whereas the Control group will continue with their usual glucose monitoring system (self-monitoring of blood glucose [SMBG] or flash glucose monitoring [FGM]).

03

Conditions studied

  • Diabetes Mellitus

Browse trials for

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Male and female participants at least 18 years of age
  • Clinically confirmed diagnosis of Type 1 or Type 2 diabetes mellitus for ≥1 year and using insulin by multiple-daily subcutaneous injections or insulin pump and an > 8% (Cohort 1)
  • Clinically confirmed diagnosis of Type 1 diabetes mellitus for ≥1 year and using insulin by multiple-daily subcutaneous injections or insulin pump and spending more than more than 1.5 hour with sensor glucose \<70 mg/dl per day including excursions below 54 mg/dl as a mean for at least 28 days (Cohort 2)
  • Participant is willing to comply with protocol

Exclusion criteria

Exclusion Criteria:

  • Female participants of childbearing capacity (defined as not surgically sterile or not menopausal for ≥ 1 year) who are lactating or pregnant, intending to become pregnant, or not practicing during the course of the study
  • A condition preventing or complicating the placement, operation or removal of the Sensor or wearing of transmitter, including upper extremity deformities or skin condition
  • History of , , or
  • Currently receiving (or likely to need during the study period): therapy; chemotherapy; anticoagulant/antithrombotic therapy (excluding aspirin \< 2000 mg per day); antibiotics for chronic infection (e.g. osteomyelitis, endocarditis)
  • A condition requiring or likely to require magnetic resonance imaging (MRI)
  • Known topical or local anesthetic allergy
  • Known allergy to or using systemic glucocorticoids (excluding topical, optical or nasal but including inhaled)
  • Any condition that in the investigator's opinion would make the participant unable to complete the study or would make it not in the participant's best interest to participate in the study. Conditions include, but are not limited to, psychiatric conditions, known current or recent alcohol abuse or drug abuse by participant history, a condition that may increase the risk of induced hypoglycemia or risk related to repeated blood testing. Investigator will supply rationale for exclusion
  • Participation in another clinical investigation (drug or device) within 2 weeks prior to screening or intent to participate during the study period
  • Legal incompetence or limited legal competence
  • Dependency on sponsor or Investigator (e.g. co-worker or family member)
  • The presence of any other active implanted device
Terms in these criteria, in plain language(7)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

HbA1c

A blood test of average blood sugar over the past two to three months, given as a percentage or in mmol/mol. 6.5% (48 mmol/mol) or more is the usual threshold for diabetes, normally confirmed by a second test.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

05

Study design

Phase
Not applicable
Primary purpose
Diagnostic
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
239 participants (actual)

Study arms

  • Experimental
    Cohort 1, Enabled - Eversense XL CGM System

    Cohort 1 included patients with clinically confirmed diagnosis of Type 1 or Type 2 diabetes mellitus for ≥1 year and using insulin by multiple-daily subcutaneous injections or insulin pump and had an HbA1c \>8%. All participants had the Eversense XL Glucose Sensor subcutaneously implanted into their arm of choice. Those randomized into the Enabled group were trained and allowed to use the Eversense XL system for continuous glucose monitoring (CGM). They were not allowed to use another CGM or FGM system.

    Device: Eversense XL CGM System

  • Active comparator
    Cohort 1, Control - Usual Glucose Monitoring System (SMBG or FGM)

    Cohort 1 included patients with clinically confirmed diagnosis of Type 1 or Type 2 diabetes mellitus for ≥1 year and using insulin by multiple-daily subcutaneous injections or insulin pump and had an HbA1c \>8%. All participants had the Eversense XL Glucose Sensor subcutaneously implanted into their arm of choice. Those randomized into the Control group were to continue using their usual glucose monitoring system (self-monitoring of blood glucose \[SMBG\] or flash glucose monitoring \[FGM\]), and the implanted Eversense XL CGM System remained in blinded mode.

    Device: Eversense XL CGM System · Device: Usual SMBG or FGM device used by participants

  • Experimental
    Cohort 2, Enabled - Eversense XL CGM System

    Cohort 2 included patients with Type 1 diabetes mellitus for ≥1 year and using insulin by multiple-daily subcutaneous injections or insulin pump and spending \>1.5 hours per day with a sensor mean glucose of \<70 mg/dL for at least 28 days (time in hypoglycemia). All participants had the Eversense XL Glucose Sensor subcutaneously implanted into their arm of choice. Those randomized into the Enabled group were trained and allowed to use the Eversense XL system for continuous glucose monitoring (CGM). They were not allowed to use another CGM or FGM system.

    Device: Eversense XL CGM System

  • Active comparator
    Cohort 2, Control - Usual Glucose Monitoring System (SMBG or FGM)

    Cohort 2 included patients with Type 1 diabetes mellitus for ≥1 year and using insulin by multiple-daily subcutaneous injections or insulin pump and spending \>1.5 hours per day with a sensor mean glucose of \<70 mg/dL for at least 28 days (time in hypoglycemia). All participants had the Eversense XL Glucose Sensor subcutaneously implanted into their arm of choice. Those randomized into the Control group were to continue using their usual glucose monitoring system (self-monitoring of blood glucose \[SMBG\] or flash glucose monitoring \[FGM\]), and the implanted Eversense XL CGM System remained in blinded mode.

    Device: Eversense XL CGM System · Device: Usual SMBG or FGM device used by participants

Interventions

  • DeviceEversense XL CGM System

    The Eversense XL Continuous Glucose Monitoring (CGM) System consists of an implantable sensor inserted under the skin, an external transmitter, and a Mobile Medical Application (MMA) for display of glucose information that runs on a Handheld Device (HHD).

  • DeviceUsual SMBG or FGM device used by participants

    Commercially available products in France for self-monitoring of blood glucose (SMBG) or flash glucose monitoring (FGM) were considered as comparators for this study.

06

What researchers measure

Primary outcomes

  1. Cohort 1: HbA1c (%) Levels at Day 180

    The analysis of the primary outcome measure for Cohort 1 was an analysis of covariance (ANCOVA) comparing the HbA1c (%), defined as the percentage of hemoglobin proteins that are glycated (i.e., chemically linked to a sugar), at the Day 180 visit between the Enabled and Control arms. The statistical model included the randomization arm, center, and diabetes type as fixed classification effects, and HbA1c (%) at Day 0 as baseline covariates. Adjusted means with their 95% confidence intervals are provided.

    Time frame: Day 180

  2. Cohort 2: Percentage of Time Spent in Hypoglycemia (<54 mg/dL) From Day 90 to Day 120

    The analysis of the primary outcome measure for Cohort 2 was an analysis of covariance (ANCOVA) comparing the percentage of time participants in each treatment arm spent in hypoglycemia with a blood glucose level \<54 milligrams per decilitre (mg/dL) between the Day 90 and Day 120 visits, based on the total duration of time with available CGM data (i.e., excluding temporary discontinuations). The statistical model included the randomization arm and center as fixed classification effects and the level of hypoglycemia at baseline (i.e. percentage of time spent in hypoglycemia \<54 mg/dL between the Day 0 and Day 30 visits) as baseline covariates. Adjusted means with their 95% confidence intervals are provided.

    Time frame: From Day 90 to Day 120

Secondary outcomes

  1. Number of Participants With at Least One Pre-Specified Adverse Event That Occurred Following Sensor Insertion

    Time frame: At sensor insertion (Day 0)

  2. Number of Participants With at Least One Pre-Specified Adverse Event That Occurred Following Sensor Removal

    Time frame: At sensor removal (up to Day 180)

  3. Overall Number of Participants With at Least One Adverse Event

    An adverse event (AE) is any untoward medical occurrence, unintended disease or injury, or untoward clinical signs (including abnormal laboratory findings) in participants, whether or not related to the investigational medical device. AEs were coded using the MedDRA dictionary version 20.1. All AEs were assessed by the investigator for relation to the device, seriousness (according to serious AE criteria), and severity (i.e., intensity of the event: mild, moderate, or severe). AEs of hypoglycemia were identified using a Standardized MedDRA Query (SMQ) for a list of Preferred Terms; all terms for hypoglycemia reported in the AE forms were considered symptomatic hypoglycemia. 'Severe hypoglycemia' included all serious and severe/life-threatening events of the SMQ for hypoglycemia. Serious diabetic ketoacidosis was identified in the AE forms using a set list of MedDRA terms. Adverse device effects (ADEs) included all AEs that were pre-specified in the electronic Case Report Form (eCRF).

    Time frame: From Day 0 (Insertion) up to Day 180; for Cohort 2, Contol: From Day 0 to Day 120 and From Day 120 to Day 180

  4. Percentage of Time Spent in the Euglycemic Range (70mg/dL-180mg/dL) From Day 90 to Day 120

    The results show an analysis of covariance (ANCOVA) comparing the percentage of time participants in each treatment arm of Cohorts 1 and 2 spent in euglycemia with a blood glucose level ≥70 mg/dL to ≤180 mg/dL between the Day 90 and Day 120 visits, based on the total duration of time with available CGM data (i.e., excluding temporary discontinuations). The statistical model included the randomization arm and centre (and diabetes type for Cohort 1) as fixed classification effects and the time in euglycemia at baseline (i.e. percentage of time spent in euglycemia between the Day 0 and Day 30 visits) as baseline covariates. Adjusted means with their 95% confidence intervals are provided.

    Time frame: From Day 90 to Day 120

  5. Percentage of Time Spent in Hyperglycemia (>250mg/dL) From Day 90 to Day 120

    The results show an analysis of covariance (ANCOVA) comparing the percentage of time participants in each treatment arm of Cohorts 1 and 2 spent in hyperglycemia with a blood glucose level \>250 mg/dL between the Day 90 and Day 120 visits, based on the total duration of time with available CGM data (i.e., excluding temporary discontinuations). The statistical model included the randomization arm and center (and diabetes type for Cohort 1) as fixed classification effects and the level of hyperglycemia at baseline (i.e. percentage of time spent in hyperglycemia \>250 mg/dL between the Day 0 and Day 30 visits) as baseline covariates. Adjusted means with their 95% confidence intervals are provided.

    Time frame: From Day 90 to Day 120

  6. Percentage of Time Spent in Hyperglycemia (>180mg/dL) From Day 90 to Day 120

    The results show an analysis of covariance (ANCOVA) comparing the percentage of time participants in each treatment arm of Cohorts 1 and 2 spent in hyperglycemia with a blood glucose level \>180 mg/dL between the Day 90 and Day 120 visits, based on the total duration of time with available CGM data (i.e., excluding temporary discontinuations). The statistical model included the randomization arm and center (and diabetes type for Cohort 1) as fixed classification effects and the level of hyperglycemia at baseline (i.e. percentage of time spent in hyperglycemia \>180 mg/dL between the Day 0 and Day 30 visits) as baseline covariate. Adjusted means with their 95% confidence intervals are provided.

    Time frame: From Day 90 to Day 120

  7. Percentage of Time Spent in Hypoglycemia (<70mg/dL) From Day 90 to Day 120

    The results show an analysis of covariance (ANCOVA) comparing the percentage of time participants in each treatment arm of Cohort 1 spent in hypoglycemia with a blood glucose level \<70 mg/dL between the Day 90 and Day 120 visits, based on the total duration of time with available CGM data (i.e., excluding temporary discontinuations). The statistical model included the randomization arm and center (and diabetes type for Cohort 1) as fixed classification effects and the level of hypoglycemia at baseline (i.e. percentage of time spent in hypoglycemia \<70 mg/dL between the Day 0 and Day 30 visits) as baseline covariate. Adjusted means with their 95% confidence intervals are provided.

    Time frame: From Day 90 to Day 120

  8. Cohort 1: Percentage of Time Spent in Hypoglycemia (<54mg/dL) From Day 90 to Day 120

    The results show an analysis of covariance (ANCOVA) comparing the percentage of time participants in each treatment arm of Cohort 1 spent in hypoglycemia with a blood glucose level \<54 mg/dL between the Day 90 and Day 120 visits, based on the total duration of time with available CGM data (i.e., excluding temporary discontinuations). The statistical model included the randomization arm, center, and diabetes type as fixed classification effects and the level of hypoglycemia at baseline (i.e. percentage of time spent in hypoglycemia \<54 mg/dL between the Day 0 and Day 30 visits) as baseline covariate. Adjusted means with their 95% confidence intervals are provided.

    Time frame: From Day 90 to Day 120

  9. Percentage of Time Spent in the Euglycemic Range (70mg/dL-180mg/dL) From Day 150 to Day 180

    The results show an analysis of covariance (ANCOVA) comparing the percentage of time participants in each treatment arm of Cohorts 1 and 2 spent in euglycemia with a blood glucose level ≥70 mg/dL to ≤180 mg/dL between the Day 150 and Day 180 visits, based on the total duration of time with available CGM data (i.e., excluding temporary discontinuations). The statistical model included the randomization arm and center (and diabetes type for Cohort 1) as fixed classification effects and the level of hypoglycemia at baseline (i.e. percentage of time spent in euglycemia between the Day 0 and Day 30 visits) as baseline covariate. Adjusted means with their 95% confidence intervals are provided.

    Time frame: From Day 150 to Day 180

  10. Percentage of Time Spent in Hyperglycemia (>250mg/dL) From Day 150 to Day 180

    The results show an analysis of covariance (ANCOVA) comparing the percentage of time participants in each treatment arm of Cohorts 1 and 2 spent in hyperglycemia with a blood glucose level \>250 mg/dL between the Day 150 and Day 180 visits, based on the total duration of time with available CGM data (i.e., excluding temporary discontinuations). The statistical model included the randomization arm and center (and diabetes type for Cohort 1) as fixed classification effects and the level of hypoglycemia at baseline (i.e. percentage of time spent in hyperglycemia \>250 mg/dL between the Day 0 and Day 30 visits) as baseline covariates. Adjusted means with their 95% confidence intervals are provided.

    Time frame: From Day 150 to Day 180

  11. Percentage of Time Spent in Hyperglycemia (>180mg/dL) From Day 150 to Day 180

    The results show an analysis of covariance (ANCOVA) comparing the percentage of time participants in each treatment arm of Cohorts 1 and 2 spent in hyperglycemia with a blood glucose level \>180 mg/dL between the Day 150 and Day 180 visits, based on the total duration of time with available CGM data (i.e., excluding temporary discontinuations). The statistical model included the randomization arm and center (and diabetes type for Cohort 1) as fixed classification effects and the level of hypoglycemia at baseline (i.e. percentage of time spent in hyperglycemia \>180 mg/dL between the Day 0 and Day 30 visits) as baseline covariate. Adjusted means with their 95% confidence intervals are provided.

    Time frame: From Day 150 to Day 180

  12. Percentage of Time Spent in Hypoglycemia (<70mg/dL) From Day 150 to Day 180

    The results show an analysis of covariance (ANCOVA) comparing the percentage of time participants in each treatment arm of Cohorts 1 and 2 spent in hypoglycemia with a blood glucose level \<70 mg/dL between the Day 150 and Day 180 visits, based on the total duration of time with available CGM data (i.e., excluding temporary discontinuations). The statistical model included the randomization arm and center (and diabetes type for Cohort 1) as fixed classification effects and the level of hypoglycemia at baseline (i.e. percentage of time spent in hypoglycemia \<70 mg/dL between the Day 0 and Day 30 visits) as baseline covariate. Adjusted means with their 95% confidence intervals are provided.

    Time frame: From Day 150 to Day 180

  13. Percentage of Time Spent in Hypoglycemia (<54mg/dL) From Day 150 to Day 180

    The results show an analysis of covariance (ANCOVA) comparing the percentage of time participants in each treatment arm of Cohorts 1 and 2 spent in hypoglycemia with a blood glucose level \<54 mg/dL between the Day 150 and Day 180 visits, based on the total duration of time with available CGM data (i.e., excluding temporary discontinuations). The statistical model included the randomization arm and center (and diabetes type for Cohort 1) as fixed classification effects and the level of hypoglycemia at baseline (i.e. percentage of time spent in hypoglycemia \<54 mg/dL between the Day 0 and Day 30 visits) as baseline covariate. Adjusted means with their 95% confidence intervals are provided.

    Time frame: From Day 150 to Day 180

  14. Cohort 2, Enabled Arm: Percentage of Time Spent in Hypoglycemia (<54 mg/dL) During the Day 90-120 Period Compared With the Day 150-180 Period for the Enabled Group

    The results show an analysis of covariance (ANCOVA) comparing the percentage of time participants in the Enabled arm of Cohort 2 spent in hypoglycemia with a blood glucose level \<54 mg/dL over two different time periods (between the Days 90-120 and Days 150-180), based on the total duration of time with available CGM data (i.e., excluding temporary discontinuations). The statistical model included the time period and center as fixed classification effects and the level of hypoglycemia at baseline (i.e. percentage of time spent in hypoglycemia \<54 mg/dL between the Day 0 and Day 30 visits) as baseline covariate. Adjusted means with their 95% confidence intervals are provided.

    Time frame: Day 90 to Day 120; Day 150 to Day 180

  15. Cohort 2, Control Arm: Percentage of Time Spent in Hypoglycemia (<54 mg/dL) During the Control Period (Days 90-120) Compared With the Enabled Period (Days 150-180) for Participants Who Switched to Use the CGM System

    The results show an analysis of covariance (ANCOVA) comparing the percentage of time participants in the Cohort 2, Control arm spent in hypoglycemia with a blood glucose level \<54 mg/dL with a different intervention over each of the two time periods (the control period, using their usual glucose monitoring system: Days 90-120, and the enabled period, using the Eversense XL CGM system: Days 150-180), based on the total duration of time with available CGM data (i.e., excluding temporary discontinuations). The statistical model included the time period and center as fixed classification effects and the level of hypoglycemia at baseline (i.e. percentage of time spent in hypoglycemia \<54 mg/dL between the Day 0 and Day 30 visits) as baseline covariate. Adjusted means with their 95% confidence intervals are provided.

    Time frame: For Cohort 2, Control arm: Day 90 to Day 120; For Cohort 2, Switch from Control to Enabled arm: Day 150 to Day 180

  16. Glucose Variability From Day 90 to Day 120, as Estimated With a Coefficient of Variation

    Glucose variability was estimated with a unitless coefficient of variation, expressed as a percentage, which was computed using CGM data with the following formula: the sum of the ratios of standard deviation of daily glycemia to the mean of daily glycemia divided by the number of days with available data for the period of interest (Days 90 to 120). According to Monnier et al. Diabetes Care 2017, a coefficient of variation threshold set to 36% allows to distinguish between stable and unstable glycemia.

    Time frame: From Day 90 to Day 120

  17. Glucose Variability From Day 150 to Day 180, as Estimated by a Coefficient of Variation

    Glucose variability was estimated with a unitless coefficient of variation, expressed as a percentage, which was computed using CGM data with the following formula: the sum of the ratios of standard deviation of daily glycemia to the mean of daily glycemia divided by the number of days with available data for the period of interest (Days 150 to 180). According to Monnier et al. Diabetes Care 2017, a coefficient of variation threshold set to 36% allows to distinguish between stable and unstable glycemia.

    Time frame: From Day 150 to Day 180

  18. HbA1c (%) Levels at Day 120

    The results show an analysis of covariance (ANCOVA) comparing the HbA1c (%), defined as the percentage of hemoglobin proteins that are glycated (i.e., chemically linked to a sugar), at the Day 120 visit between the Enabled and Control arms for Cohorts 1 and 2. The statistical model included the randomization arm and center (and diabetes type for Cohort 1) as fixed classification effects, and HbA1c (%) at Day 0 as baseline covariates. Adjusted means with their 95% confidence interval are provided.

    Time frame: Day 120

  19. Cohort 2: HbA1c (%) Levels at Day 180

    The analysis of this secondary outcome measure for Cohort 2 was an analysis of covariance (ANCOVA) comparing the HbA1c (%), defined as the percentage of hemoglobin proteins that are glycated (i.e., chemically linked to a sugar), at the Day 180 visit between the Enabled and Control arms. The statistical model included the randomization arm and center as fixed classification effects, and HbA1c (%) at Day 0 as baseline covariates. Adjusted means with their 95% confidence interval are provided.

    Time frame: Day 180

  20. Number of Participants With the First Sensor Operating at Day 150 and Day 180

    This measure assesses sensor life by counting the number of participants with their first inserted CGM sensor still operating at 150 days and at 180 days post-insertion. The assessment was based on the lifespan of the first sensor: for example, if lifespan of the first sensor was ≥150 days and ≥180 days, then the participant was counted as having their first sensor operating at 150 days and 180 days, respectively. The lifespan of the first inserted CGM sensor for each participant, measured in days, was calculated as the date of the last glucose measurement by the sensor minus the date of the first glucose measurement by the sensor (+1 day).

    Time frame: From Day 0 up to Day 150 and Day 180

  21. Mean Lifespan of the First Sensor

    The lifespan of the first inserted CGM sensor for each participant, measured in days, was calculated as the date of the last glucose measurement by the sensor minus the date of the first glucose measurement by the sensor (+1 day).

    Time frame: From Day 0 up to Day 180

  22. Median Number of Sensors Used by Each Participant During the Study

    Time frame: From Day 0 to Day 180

  23. Number of Participants With the First Transmitter Operating at Day 150 and Day 180

    This measure assesses transmitter wear time by counting the number of participants with their first CGM transmitter still operating at 150 days and at 180 days after first use. The assessment was based on the lifespan of the first transmitter: for example, if lifespan of the first transmitter was ≥150 days and ≥180 days, then the participant was counted as having their first transmitter operating at 150 days and 180 days, respectively. The lifespan of the first CGM transmitter for each participant, measured in days, was calculated as the date of the last glucose measurement with the transmitter minus the date of the first glucose measurement with the transmitter (+1 day).

    Time frame: From Day 0 up to Day 150 and Day 180

  24. Mean Lifespan of the First Transmitter

    The lifespan of the first CGM transmitter for each participant, measured in days, was calculated as the date of the last glucose measurement with the transmitter minus the date of the first glucose measurement with the transmitter (+1 day).

    Time frame: From Day 0 up to Day 180

  25. Median Number of Transmitters Used by Each Participant During the Study

    Time frame: From Day 0 to Day 180

  26. Number of Participants Who Accessed CGM Application Pages at Days 60, 120, and 180

    This was a descriptive analysis of the number of participants in the Eversense XL CGM System Enabled groups who accessed the various CGM application (app) pages/functions at study Days 60, 120, and 180. The data were collected in the electronic Case Report Form.

    Time frame: At Days 60, 120, and 180

  27. Number of Participants Issued at Least One Type of Alarm or Alert by the CGM System During the Study

    This outcome measure is a descriptive analysis of the number of participants who were issued various types of alarms and alerts by the Eversense XL CGM System through the mobile medical application. The alarms listed in the results table are a higher level classification for the different types of alerts that immediately follow it, until the next type of alarm is listed (for example, the 'Calibration' alarm included both 'Calibrate Now' and 'Calibration Past Due' alerts). Only participants in the Enabled groups of both cohorts actually received these alarms/alerts because the CGM remained in blinded mode for participants in the Control groups.

    Time frame: From Day 0 up to Day 180

  28. Diabetes Treatment Satisfaction Questionnaire - Original Status (DTSQs) Treatment Satisfaction Score at Baseline, Day 60, and Day 180

    The DTSQs questionnaire contains eight items scored on a 7-point scale (i.e. each item is scored from 0 to 6). Six items measure Treatment Satisfaction, dealing with: satisfaction with current treatment; convenience of the treatment; flexibility; satisfaction with own understanding of participant's diabetes; how likely to recommend their present treatment; and how satisfied to continue with their present treatment. These are summed to produce a total Treatment Satisfaction score, with a minimum value of 0 and a maximum value of 36; a higher score indicates greater treatment satisfaction. In case of missing items, the overall score was calculated as the mean of the available items.

    Time frame: Baseline (Day 0), Day 60, and Day 180

  29. Change From Baseline in the DTSQs Treatment Satisfaction Score at Day 60 and Day 180

    The DTSQs questionnaire contains eight items scored on a 7-point scale (i.e. each item is scored from 0 to 6). Six items measure Treatment Satisfaction (dealing with: satisfaction with current treatment; convenience of the treatment; flexibility; satisfaction with own understanding of participant's diabetes; how likely to recommend their present treatment; and how satisfied to continue with their present treatment). These are summed to produce a total Treatment Satisfaction score, with a minimum value of 0 and a maximum value of 36; a higher score indicates greater treatment satisfaction. For the change from baseline analysis, a positive value indicates an improvement in treatment satisfaction. In case of missing items, the overall score was calculated as the mean of the available items.

    Time frame: Baseline (Day 0), Day 60, and Day 180

  30. Diabetes Treatment Satisfaction Questionnaire - Change Version (DTSQc) Treatment Satisfaction Score at Day 180

    The DTSQc questionnaire contains eight items scored on a 7-point scale (i.e. each item is scored from -3 to +3). Six items measure Treatment Satisfaction (dealing with: satisfaction with current treatment; convenience of the treatment; flexibility; satisfaction with own understanding of participant's diabetes; how likely to recommend their present treatment; and how satisfied to continue with their present treatment). These are summed to produce a total Treatment Satisfaction score, with a minimum value of -18 and a maximum value of +18; a higher score indicates greater treatment satisfaction. In case of missing items, the overall score was calculated as the mean of the available items.

    Time frame: Day 180

  31. Audit of Diabetes-Dependent Quality of Life (ADDQoL) Score at Baseline and Day 180

    The ADDQoL measures the impact of diabetes and its treatment on 19 specific aspects of life. The scale ranges from -3 to +1 for 19 life domains (impact rating) and from 0 to +3 in attributed importance (importance rating). A weighted score for each domain is calculated as a multiplier of impact rating and importance rating (ranging from -9 to +3). Finally, a mean weighted impact score (ADDQOL score) is calculated for the entire scale across all applicable domains; a higher score indicates greater quality of life.

    Time frame: Baseline (Day 0) and Day 180

  32. Change From Baseline in the Audit of Diabetes-Dependent Quality of Life (ADDQoL) Score at Day 180

    The ADDQoL measures the impact of diabetes and its treatment on 19 specific aspects of life. The scale ranges from -3 to +1 for 19 life domains (impact rating) and from 0 to +3 in attributed importance (importance rating). A weighted score for each domain is calculated as a multiplier of impact rating and importance rating (ranging from -9 to +3). Finally, a mean weighted impact score (ADDQOL score) is calculated for the entire scale across all applicable domains; a higher score indicates greater quality of life. For the change from baseline analysis, a positive value indicates an improvement in quality of life.

    Time frame: Baseline (Day 0) and Day 180

  33. The Continuous Glucose Monitoring Satisfaction (CGM-SAT) Questionnaire Overall Score at Day 60 and Day 180

    The CGM-SAT questionnaire comprises 44 item scales assessing experiences with CGM over the previous 6 months. The scale is designed to measure the impact of CGM on diabetes management and family relationships, plus on satisfaction with emotional, behavioral and cognitive effects of CGM use. The responses were rated on a 5-point scale from '1 = strongly agree' to '5 = strongly disagree'. The overall score corresponds to the mean of the 44 items of potential positive or negative effects of using the CGM device; a higher score reflects more favorable impact of, and satisfaction with CGM. In case of missing items, the overall score was calculated as the mean of the available items.

    Time frame: Day 60 and Day 180

  34. Change From Day 60 in the CGM-SAT Questionnaire Overall Score at Day 180

    The CGM-SAT questionnaire comprises 44 item scales assessing experiences with CGM over the previous 6 months. The scale is designed to measure the impact of CGM on diabetes management and family relationships, plus on satisfaction with emotional, behavioral and cognitive effects of CGM use. The responses were rated on a 5-point scale from '1 = strongly agree' to '5 = strongly disagree'. The overall score corresponds to the mean of the 44 items of potential positive or negative effects of using the CGM device; a higher score (or positive change from baseline score) reflects more favorable impact of, and satisfaction with CGM. In case of missing items, the overall score was calculated as the mean of the available items.

    Time frame: Day 60 and Day 180

  35. Diabetes Distress Scale 2 (DDS2) Questionnaire Score at Baseline, Day 60, and Day 180

    The DDS2 is a 2-item diabetes distress screening instrument asking respondents to rate on a 6-point scale (from 1 = 'Not a problem' to 6 = 'A very serious problem') the degree to which the following items caused distress: (1) feeling overwhelmed by the demands of living with diabetes, and (2) feeling that I am often failing with my diabetes regimen. The DDS2 score is the mean of the two items (ranging from 1 to 6). A lower DDS2 score (or a negative change from baseline score) indicates a lower level of distress. If one item was missing, then no score was computed.

    Time frame: Baseline (Day 0), Day 60, and Day 180

  36. Change From Baseline in the Diabetes Distress Scale 2 (DDS2) Questionnaire Score at Day 60 and Day 180

    The DDS2 is a 2-item diabetes distress screening instrument asking respondents to rate on a 6-point scale (from 1 = 'Not a problem' to 6 = 'A very serious problem') the degree to which the following items caused distress: (1) feeling overwhelmed by the demands of living with diabetes, and (2) feeling that I am often failing with my diabetes regimen. The DDS2 score is the mean of the two items (ranging from 1 to 6). A lower DDS2 score (or a negative change from baseline score) indicates a lower level of distress. If one item was missing, then no score was computed.

    Time frame: Baseline (Day 0), Day 60, and Day 180

  37. Hypoglycemia Fear Survey, Part 2 (HFS2) Worry Subscale Score at Baseline, Day 60, and Day 180

    HFS2 Worry items describe specific concerns that patients may have about their hypoglycemic episodes (e.g., being alone, episodes occurring during sleep, or having an accident). The 5-point Likert scale for each item ranges from 0 (never) to 4 (almost always), and the HFS2 Worry subscale score is the sum of all 18 items (ranging from 0 to 72). A lower HFS2 Worry subscale score (or a negative change from baseline score) indicates a lower level of fear of hypoglycemia. There was no plan to replace missing items: if one item was missing, the score was not computed.

    Time frame: Baseline (Day 0), Day 60, and Day 180

  38. Change From Baseline in the Hypoglycemia Fear Survey, Part 2 (HFS2) Worry Subscale Score at Day 60 and Day 180

    HFS2 Worry items describe specific concerns that patients may have about their hypoglycemic episodes (e.g., being alone, episodes occurring during sleep, or having an accident). The 5-point Likert scale for each item ranges from 0 (never) to 4 (almost always), and the HFS2 Worry subscale score is the sum of all 18 items (ranging from 0 to 72). A lower HFS2 Worry subscale score (or a negative change from baseline score) indicates a lower level of fear of hypoglycemia. There was no plan to replace missing items: if one item was missing, the score was not computed.

    Time frame: Baseline (Day 0), Day 60, and Day 180

  39. Change From Baseline in the Partner Diabetes Distress Scale (Partner-DDS) Questionnaire Total and Subscale Scores at Day 60 and Day 180

    The Partner-DDS is a 21-item self-report scale that highlights four critical dimensions of partner-related distress: "my partner's diabetes management", "how best to help", "diabetes and me", and "hypoglycemia". The scale ranges from 0 (not at all) to 4 (a great deal). The Partner-DDS yields a total diabetes distress score plus 4 subscale scores: Total Partner-DDS Score = Mean of the 21 items; My partner's diabetes management = Mean of item 3, 4, 10, 12, 14, 15 and 20; How best to help = Mean of item 2, 6, 7, 11 and 13; Diabetes and me = Mean of items 5, 8, 9, 16 and 21; Hypoglycemia = Mean of items 1, 17, 18 and 19. A lower Partner-DDS score (or a negative change from baseline score) indicates a lower level of distress.

    Time frame: Baseline (Day 0), Day 60, and Day 180

07

Results

Posted Sep 10, 2021

Participant flow

Participant flow — Overall Study
MilestoneCohort 1, Enabled - Eversense XL CGM SystemCohort 1, Control - Usual Glucose Monitoring System (SMBG or FGM)Cohort 2, Enabled - Eversense XL CGM SystemCohort 2, Control - Usual Glucose Monitoring System (SMBG or FGM)
Started97526228
Completed90435725
Not completed7953
Withdrew: Withdrawal by subject3622
Withdrew: Other4331

Outcome measures

PrimaryCohort 1: HbA1c (%) Levels at Day 180

The analysis of the primary outcome measure for Cohort 1 was an analysis of covariance (ANCOVA) comparing the HbA1c (%), defined as the percentage of hemoglobin proteins that are glycated (i.e., chemically linked to a sugar), at the Day 180 visit between the Enabled and Control arms. The statistical model included the randomization arm, center, and diabetes type as fixed classification effects, and HbA1c (%) at Day 0 as baseline covariates. Adjusted means with their 95% confidence intervals are provided.

Time frame:
Day 180
Reported as:
Mean · HbA1c (%)
Cohort 1: HbA1c (%) Levels at Day 180
HbA1c (%)Cohort 1, Enabled - Eversense XL CGM SystemCohort 1, Control - Usual Glucose Monitoring System (SMBG or FGM)
Cohort 1: HbA1c (%) Levels at Day 1808.6 (8.4 to 8.9)8.8 (8.5 to 9.0)
Statistical analysis
  • Cohort 1, Enabled - Eversense XL CGM System vs Cohort 1, Control - Usual Glucose Monitoring System (SMBG or FGM) · ANCOVA · p = 0.341 (The significance level was set to p\<0.05 (two-sided).) · Mean difference (net): -0.1 · 95% CI -0.4 to 0.1The mean difference in HbA1c (%) at Day 180 was calculated as the Enabled group minus the Control group.
PrimaryCohort 2: Percentage of Time Spent in Hypoglycemia (<54 mg/dL) From Day 90 to Day 120

The analysis of the primary outcome measure for Cohort 2 was an analysis of covariance (ANCOVA) comparing the percentage of time participants in each treatment arm spent in hypoglycemia with a blood glucose level \<54 milligrams per decilitre (mg/dL) between the Day 90 and Day 120 visits, based on the total duration of time with available CGM data (i.e., excluding temporary discontinuations). The statistical model included the randomization arm and center as fixed classification effects and the level of hypoglycemia at baseline (i.e. percentage of time spent in hypoglycemia \<54 mg/dL between the Day 0 and Day 30 visits) as baseline covariates. Adjusted means with their 95% confidence intervals are provided.

Time frame:
From Day 90 to Day 120
Reported as:
Mean · Percentage of time
Cohort 2: Percentage of Time Spent in Hypoglycemia (<54 mg/dL) From Day 90 to Day 120
Percentage of timeCohort 2, Enabled - Eversense XL CGM SystemCohort 2, Control - Usual Glucose Monitoring System (SMBG or FGM)
Cohort 2: Percentage of Time Spent in Hypoglycemia (<54 mg/dL) From Day 90 to Day 1204.0 (3.0 to 5.1)5.7 (4.2 to 7.1)
Statistical analysis
  • Cohort 2, Enabled - Eversense XL CGM System vs Cohort 2, Control - Usual Glucose Monitoring System (SMBG or FGM) · ANCOVA · p = 0.03892 (The significance level was set to p\<0.05 (two-sided).) · Mean difference (net): -1.6 · 95% CI -3.1 to -0.1The mean difference was calculated as the Enabled group minus the Control group.
SecondaryNumber of Participants With at Least One Pre-Specified Adverse Event That Occurred Following Sensor Insertion
Time frame:
At sensor insertion (Day 0)
Reported as:
Count of participants · Participants
Number of Participants With at Least One Pre-Specified Adverse Event That Occurred Following Sensor Insertion
ParticipantsCohort 1, Enabled - Eversense XL CGM SystemCohort 1, Control - Usual Glucose Monitoring System (SMBG or FGM)Cohort 2, Enabled - Eversense XL CGM SystemCohort 2, Control - Usual Glucose Monitoring System (SMBG or FGM)
At Least One Infection, Local or Systemic1110
At Least One Bleeding0001
At Least One Edema or Swelling0100
At Least One Scar Formation and/or Keloid0000
At Least One Skin Irritation and/or Redness4110
At Least One Nerve Damage Causing Tingling, Numbness, Pain, or Weakness1000
At Least One Itching and/or Pruritus2021
At Least One Discoloration of Skin0100
At Least One Hematoma Formation0230
At Least One Pain and/or Burning Sensation1100
At Least One Device Migration0000
SecondaryNumber of Participants With at Least One Pre-Specified Adverse Event That Occurred Following Sensor Removal
Time frame:
At sensor removal (up to Day 180)
Reported as:
Count of participants · Participants
Number of Participants With at Least One Pre-Specified Adverse Event That Occurred Following Sensor Removal
ParticipantsCohort 1, Enabled - Eversense XL CGM SystemCohort 1, Control - Usual Glucose Monitoring System (SMBG or FGM)Cohort 2, Enabled - Eversense XL CGM SystemCohort 2, Control - Usual Glucose Monitoring System (SMBG or FGM)
At Least One Infection, Local or Systemic0000
At Least One Bleeding0000
At Least One Edema or Swelling0000
At Least One Scar Formation and/or Keloid0000
At Least One Skin Irritation and/or Redness0000
At Least One Nerve Damage Causing Tingling, Numbness, Pain, or Weakness0000
At Least One Itching and/or Pruritus0000
At Least One Discoloration of Skin0000
At Least One Hematoma Formation0100
At Least One Pain and/or Burning Sensation1110
At Least One Device Migration0000
SecondaryOverall Number of Participants With at Least One Adverse Event

An adverse event (AE) is any untoward medical occurrence, unintended disease or injury, or untoward clinical signs (including abnormal laboratory findings) in participants, whether or not related to the investigational medical device. AEs were coded using the MedDRA dictionary version 20.1. All AEs were assessed by the investigator for relation to the device, seriousness (according to serious AE criteria), and severity (i.e., intensity of the event: mild, moderate, or severe). AEs of hypoglycemia were identified using a Standardized MedDRA Query (SMQ) for a list of Preferred Terms; all terms for hypoglycemia reported in the AE forms were considered symptomatic hypoglycemia. 'Severe hypoglycemia' included all serious and severe/life-threatening events of the SMQ for hypoglycemia. Serious diabetic ketoacidosis was identified in the AE forms using a set list of MedDRA terms. Adverse device effects (ADEs) included all AEs that were pre-specified in the electronic Case Report Form (eCRF).

Time frame:
From Day 0 (Insertion) up to Day 180; for Cohort 2, Contol: From Day 0 to Day 120 and From Day 120 to Day 180
Reported as:
Count of participants · Participants
Overall Number of Participants With at Least One Adverse Event
ParticipantsCohort 1, Enabled - Eversense XL CGM SystemCohort 1, Control - Usual Glucose Monitoring System (SMBG or FGM)Cohort 2, Enabled - Eversense XL CGM SystemCohort 2, Control (Day 0 to 120) - Usual Glucose Monitoring System (SMBG or FGM)Cohort 2, Control (Day 120 to 180) - Eversense XL CGM System or Usual Glucose Monitoring System
At Least One AE46192592
At Least One Serious AE75200
At Least One Fatal AE00000
At Least One Mild AE (Maximum Severity)27141481
At Least One Moderate AE (Maximum Severity)2881431
At Least One Severe AE (Maximum Severity)65200
At Least One AE Leading to Discontinuation of Device24010
At Least One AE Related (Possible or Probable) to Device1571130
At Least One AE of Symptomatic Hypoglycemia22421
At Least One AE of Severe Hypoglycemia01000
At Least One AE of Serious Diabetic Ketoacidosis10000
At Least One Adverse Device Effect (ADE), Collected in the eCRF593040135
At Least One ADE, Reported to the Hotline39172875
SecondaryPercentage of Time Spent in the Euglycemic Range (70mg/dL-180mg/dL) From Day 90 to Day 120

The results show an analysis of covariance (ANCOVA) comparing the percentage of time participants in each treatment arm of Cohorts 1 and 2 spent in euglycemia with a blood glucose level ≥70 mg/dL to ≤180 mg/dL between the Day 90 and Day 120 visits, based on the total duration of time with available CGM data (i.e., excluding temporary discontinuations). The statistical model included the randomization arm and centre (and diabetes type for Cohort 1) as fixed classification effects and the time in euglycemia at baseline (i.e. percentage of time spent in euglycemia between the Day 0 and Day 30 visits) as baseline covariates. Adjusted means with their 95% confidence intervals are provided.

Time frame:
From Day 90 to Day 120
Reported as:
Mean · Percentage of time
Percentage of Time Spent in the Euglycemic Range (70mg/dL-180mg/dL) From Day 90 to Day 120
Percentage of timeCohort 1, Enabled - Eversense XL CGM SystemCohort 1, Control - Usual Glucose Monitoring System (SMBG or FGM)Cohort 2, Enabled - Eversense XL CGM SystemCohort 2, Control - Usual Glucose Monitoring System (SMBG or FGM)
Percentage of Time Spent in the Euglycemic Range (70mg/dL-180mg/dL) From Day 90 to Day 12047.4 (42.0 to 52.9)42.1 (35.8 to 48.4)59.8 (57.2 to 62.3)55.0 (51.5 to 58.6)
Statistical analysis
  • Cohort 1, Enabled - Eversense XL CGM System vs Cohort 1, Control - Usual Glucose Monitoring System (SMBG or FGM) · ANCOVA · p = 0.056 (The significance level was set to p\<0.05 (two-sided).) · Mean difference (net): 5.4 · 95% CI -0.1 to 10.9The mean difference was calculated as the Enabled group minus the Control group.
  • Cohort 2, Enabled - Eversense XL CGM System vs Cohort 2, Control - Usual Glucose Monitoring System (SMBG or FGM) · ANCOVA · p = 0.01255 (The significance level was set to p\<0.05 (two-sided).) · Mean difference (net): 4.7 · 95% CI 1.0 to 8.4The mean difference was calculated as the Enabled group minus the Control group.
SecondaryPercentage of Time Spent in Hyperglycemia (>250mg/dL) From Day 90 to Day 120

The results show an analysis of covariance (ANCOVA) comparing the percentage of time participants in each treatment arm of Cohorts 1 and 2 spent in hyperglycemia with a blood glucose level \>250 mg/dL between the Day 90 and Day 120 visits, based on the total duration of time with available CGM data (i.e., excluding temporary discontinuations). The statistical model included the randomization arm and center (and diabetes type for Cohort 1) as fixed classification effects and the level of hyperglycemia at baseline (i.e. percentage of time spent in hyperglycemia \>250 mg/dL between the Day 0 and Day 30 visits) as baseline covariates. Adjusted means with their 95% confidence intervals are provided.

Time frame:
From Day 90 to Day 120
Reported as:
Mean · Percentage of time
Percentage of Time Spent in Hyperglycemia (>250mg/dL) From Day 90 to Day 120
Percentage of timeCohort 1, Enabled - Eversense XL CGM SystemCohort 1, Control - Usual Glucose Monitoring System (SMBG or FGM)Cohort 2, Enabled - Eversense XL CGM SystemCohort 2, Control - Usual Glucose Monitoring System (SMBG or FGM)
Percentage of Time Spent in Hyperglycemia (>250mg/dL) From Day 90 to Day 12018.5 (14.1 to 22.9)24.0 (19.0 to 29.1)8.5 (6.4 to 10.6)9.5 (6.7 to 12.4)
Statistical analysis
  • Cohort 1, Enabled - Eversense XL CGM System vs Cohort 1, Control - Usual Glucose Monitoring System (SMBG or FGM) · ANCOVA · p = 0.015 (The significance level was set to p\<0.05 (two-sided).) · Mean difference (net): -5.5 · 95% CI -9.9 to -1.1The mean difference was calculated as the Enabled group minus the Control group.
  • Cohort 2, Enabled - Eversense XL CGM System vs Cohort 2, Control - Usual Glucose Monitoring System (SMBG or FGM) · ANCOVA · p = 0.50266 (The significance level was set to p\<0.05 (two-sided).) · Mean difference (net): -1.0 · 95% CI -4.0 to 2.0The mean difference was calculated as the Enabled group minus the Control group.
SecondaryPercentage of Time Spent in Hyperglycemia (>180mg/dL) From Day 90 to Day 120

The results show an analysis of covariance (ANCOVA) comparing the percentage of time participants in each treatment arm of Cohorts 1 and 2 spent in hyperglycemia with a blood glucose level \>180 mg/dL between the Day 90 and Day 120 visits, based on the total duration of time with available CGM data (i.e., excluding temporary discontinuations). The statistical model included the randomization arm and center (and diabetes type for Cohort 1) as fixed classification effects and the level of hyperglycemia at baseline (i.e. percentage of time spent in hyperglycemia \>180 mg/dL between the Day 0 and Day 30 visits) as baseline covariate. Adjusted means with their 95% confidence intervals are provided.

Time frame:
From Day 90 to Day 120
Reported as:
Mean · Percentage of time
Percentage of Time Spent in Hyperglycemia (>180mg/dL) From Day 90 to Day 120
Percentage of timeCohort 1, Enabled - Eversense XL CGM SystemCohort 1, Control - Usual Glucose Monitoring System (SMBG or FGM)Cohort 2, Enabled - Eversense XL CGM SystemCohort 2, Control - Usual Glucose Monitoring System (SMBG or FGM)
Percentage of Time Spent in Hyperglycemia (>180mg/dL) From Day 90 to Day 12050.0 (44.3 to 55.8)55.2 (48.6 to 61.8)30.7 (28.0 to 33.5)34.0 (30.2 to 37.9)
Statistical analysis
  • Cohort 1, Enabled - Eversense XL CGM System vs Cohort 1, Control - Usual Glucose Monitoring System (SMBG or FGM) · ANCOVA · p = 0.080 (The significance level was set to p\<0.05 (two-sided).) · Mean difference (net): -5.1 · 95% CI -10.9 to 0.6The mean difference was calculated as the Enabled group minus the Control group.
  • Cohort 2, Enabled - Eversense XL CGM System vs Cohort 2, Control - Usual Glucose Monitoring System (SMBG or FGM) · ANCOVA · p = 0.10637 (The significance level was set to p\<0.05 (two-sided).) · Mean difference (net): -3.3 · 95% CI -7.3 to 0.7The mean difference was calculated as the Enabled group minus the Control group.
SecondaryPercentage of Time Spent in Hypoglycemia (<70mg/dL) From Day 90 to Day 120

The results show an analysis of covariance (ANCOVA) comparing the percentage of time participants in each treatment arm of Cohort 1 spent in hypoglycemia with a blood glucose level \<70 mg/dL between the Day 90 and Day 120 visits, based on the total duration of time with available CGM data (i.e., excluding temporary discontinuations). The statistical model included the randomization arm and center (and diabetes type for Cohort 1) as fixed classification effects and the level of hypoglycemia at baseline (i.e. percentage of time spent in hypoglycemia \<70 mg/dL between the Day 0 and Day 30 visits) as baseline covariate. Adjusted means with their 95% confidence intervals are provided.

Time frame:
From Day 90 to Day 120
Reported as:
Mean · Percentage of time
Percentage of Time Spent in Hypoglycemia (<70mg/dL) From Day 90 to Day 120
Percentage of timeCohort 1, Enabled - Eversense XL CGM SystemCohort 1, Control - Usual Glucose Monitoring System (SMBG or FGM)Cohort 2, Enabled - Eversense XL CGM SystemCohort 2, Control - Usual Glucose Monitoring System (SMBG or FGM)
Percentage of Time Spent in Hypoglycemia (<70mg/dL) From Day 90 to Day 1202.6 (1.6 to 3.5)2.8 (1.7 to 3.9)9.5 (7.9 to 11.1)11.3 (9.1 to 13.5)
Statistical analysis
  • Cohort 1, Enabled - Eversense XL CGM System vs Cohort 1, Control - Usual Glucose Monitoring System (SMBG or FGM) · ANCOVA · p = 0.671 (The significance level was set to p\<0.05 (two-sided).) · Mean difference (net): -0.2 · 95% CI -1.2 to 0.7The mean difference was calculated as the Enabled group minus the Control group.
  • Cohort 2, Enabled - Eversense XL CGM System vs Cohort 2, Control - Usual Glucose Monitoring System (SMBG or FGM) · ANCOVA · p = 0.12935 (The significance level was set to p\<0.05 (two-sided).) · Mean difference (net): -1.8 · 95% CI -4.1 to 0.5The mean difference was calculated as the Enabled group minus the Control group.
SecondaryCohort 1: Percentage of Time Spent in Hypoglycemia (<54mg/dL) From Day 90 to Day 120

The results show an analysis of covariance (ANCOVA) comparing the percentage of time participants in each treatment arm of Cohort 1 spent in hypoglycemia with a blood glucose level \<54 mg/dL between the Day 90 and Day 120 visits, based on the total duration of time with available CGM data (i.e., excluding temporary discontinuations). The statistical model included the randomization arm, center, and diabetes type as fixed classification effects and the level of hypoglycemia at baseline (i.e. percentage of time spent in hypoglycemia \<54 mg/dL between the Day 0 and Day 30 visits) as baseline covariate. Adjusted means with their 95% confidence intervals are provided.

Time frame:
From Day 90 to Day 120
Reported as:
Mean · Percentage of time
Cohort 1: Percentage of Time Spent in Hypoglycemia (<54mg/dL) From Day 90 to Day 120
Percentage of timeCohort 1, Enabled - Eversense XL CGM SystemCohort 1, Control - Usual Glucose Monitoring System (SMBG or FGM)
Cohort 1: Percentage of Time Spent in Hypoglycemia (<54mg/dL) From Day 90 to Day 1201.1 (0.5 to 1.6)1.2 (0.5 to 1.8)
Statistical analysis
  • Cohort 1, Enabled - Eversense XL CGM System vs Cohort 1, Control - Usual Glucose Monitoring System (SMBG or FGM) · ANCOVA · p = 0.693 (The significance level was set to p\<0.05 (two-sided).) · Mean difference (net): -0.1 · 95% CI -0.6 to 0.4The mean difference was calculated as the Enabled group minus the Control group.
SecondaryPercentage of Time Spent in the Euglycemic Range (70mg/dL-180mg/dL) From Day 150 to Day 180

The results show an analysis of covariance (ANCOVA) comparing the percentage of time participants in each treatment arm of Cohorts 1 and 2 spent in euglycemia with a blood glucose level ≥70 mg/dL to ≤180 mg/dL between the Day 150 and Day 180 visits, based on the total duration of time with available CGM data (i.e., excluding temporary discontinuations). The statistical model included the randomization arm and center (and diabetes type for Cohort 1) as fixed classification effects and the level of hypoglycemia at baseline (i.e. percentage of time spent in euglycemia between the Day 0 and Day 30 visits) as baseline covariate. Adjusted means with their 95% confidence intervals are provided.

Time frame:
From Day 150 to Day 180
Reported as:
Mean · Percentage of time
Percentage of Time Spent in the Euglycemic Range (70mg/dL-180mg/dL) From Day 150 to Day 180
Percentage of timeCohort 1, Enabled - Eversense XL CGM SystemCohort 1, Control - Usual Glucose Monitoring System (SMBG or FGM)Cohort 2, Enabled - Eversense XL CGM SystemCohort 2, Control - Usual Glucose Monitoring System (SMBG or FGM)
Percentage of Time Spent in the Euglycemic Range (70mg/dL-180mg/dL) From Day 150 to Day 18047.0 (41.3 to 52.8)48.0 (41.4 to 54.6)60.7 (57.8 to 63.6)61.1 (57.1 to 65.1)
Statistical analysis
  • Cohort 1, Enabled - Eversense XL CGM System vs Cohort 1, Control - Usual Glucose Monitoring System (SMBG or FGM) · ANCOVA · p = 0.753 (The significance level was set to p\<0.05 (two-sided).) · Mean difference (net): -0.9 · 95% CI -6.7 to 4.9The mean difference was calculated as the Enabled group minus the Control group.
  • Cohort 2, Enabled - Eversense XL CGM System vs Cohort 2, Control - Usual Glucose Monitoring System (SMBG or FGM) · ANCOVA · p = 0.84307 (The significance level was set to p\<0.05 (two-sided).) · Mean difference (net): -0.4 · 95% CI -4.6 to 3.8The mean difference was calculated as the Enabled group minus the Control group.
SecondaryPercentage of Time Spent in Hyperglycemia (>250mg/dL) From Day 150 to Day 180

The results show an analysis of covariance (ANCOVA) comparing the percentage of time participants in each treatment arm of Cohorts 1 and 2 spent in hyperglycemia with a blood glucose level \>250 mg/dL between the Day 150 and Day 180 visits, based on the total duration of time with available CGM data (i.e., excluding temporary discontinuations). The statistical model included the randomization arm and center (and diabetes type for Cohort 1) as fixed classification effects and the level of hypoglycemia at baseline (i.e. percentage of time spent in hyperglycemia \>250 mg/dL between the Day 0 and Day 30 visits) as baseline covariates. Adjusted means with their 95% confidence intervals are provided.

Time frame:
From Day 150 to Day 180
Reported as:
Mean · Percentage of time
Percentage of Time Spent in Hyperglycemia (>250mg/dL) From Day 150 to Day 180
Percentage of timeCohort 1, Enabled - Eversense XL CGM SystemCohort 1, Control - Usual Glucose Monitoring System (SMBG or FGM)Cohort 2, Enabled - Eversense XL CGM SystemCohort 2, Control - Usual Glucose Monitoring System (SMBG or FGM)
Percentage of Time Spent in Hyperglycemia (>250mg/dL) From Day 150 to Day 18018.5 (14.6 to 22.5)19.4 (14.9 to 23.9)8.7 (6.9 to 10.4)6.3 (3.9 to 8.8)
Statistical analysis
  • Cohort 1, Enabled - Eversense XL CGM System vs Cohort 1, Control - Usual Glucose Monitoring System (SMBG or FGM) · ANCOVA · p = 0.653 (The significance level was set to p\<0.05 (two-sided).) · Mean difference (net): -0.9 · 95% CI -4.8 to 3.0The mean difference was calculated as the Enabled group minus the Control group.
  • Cohort 2, Enabled - Eversense XL CGM System vs Cohort 2, Control - Usual Glucose Monitoring System (SMBG or FGM) · ANCOVA · p = 0.07261 (The significance level was set to p\<0.05 (two-sided).) · Mean difference (net): 2.3 · 95% CI -0.2 to 4.8The mean difference was calculated as the Enabled group minus the Control group.
SecondaryPercentage of Time Spent in Hyperglycemia (>180mg/dL) From Day 150 to Day 180

The results show an analysis of covariance (ANCOVA) comparing the percentage of time participants in each treatment arm of Cohorts 1 and 2 spent in hyperglycemia with a blood glucose level \>180 mg/dL between the Day 150 and Day 180 visits, based on the total duration of time with available CGM data (i.e., excluding temporary discontinuations). The statistical model included the randomization arm and center (and diabetes type for Cohort 1) as fixed classification effects and the level of hypoglycemia at baseline (i.e. percentage of time spent in hyperglycemia \>180 mg/dL between the Day 0 and Day 30 visits) as baseline covariate. Adjusted means with their 95% confidence intervals are provided.

Time frame:
From Day 150 to Day 180
Reported as:
Mean · Percentage of time
Percentage of Time Spent in Hyperglycemia (>180mg/dL) From Day 150 to Day 180
Percentage of timeCohort 1, Enabled - Eversense XL CGM SystemCohort 1, Control - Usual Glucose Monitoring System (SMBG or FGM)Cohort 2, Enabled - Eversense XL CGM SystemCohort 2, Control - Usual Glucose Monitoring System (SMBG or FGM)
Percentage of Time Spent in Hyperglycemia (>180mg/dL) From Day 150 to Day 18050.8 (44.7 to 56.8)49.5 (42.5 to 56.5)30.9 (27.6 to 34.2)27.8 (23.3 to 32.3)
Statistical analysis
  • Cohort 1, Enabled - Eversense XL CGM System vs Cohort 1, Control - Usual Glucose Monitoring System (SMBG or FGM) · ANCOVA · p = 0.685 (The significance level was set to p\<0.05 (two-sided).) · Mean difference (net): 1.3 · 95% CI -4.9 to 7.4The mean difference was calculated as the Enabled group minus the Control group.
  • Cohort 2, Enabled - Eversense XL CGM System vs Cohort 2, Control - Usual Glucose Monitoring System (SMBG or FGM) · ANCOVA · p = 0.19785 (The significance level was set to p\<0.05 (two-sided).) · Mean difference (net): 3.1 · 95% CI -1.6 to 7.8The mean difference was calculated as the Enabled group minus the Control group.
SecondaryPercentage of Time Spent in Hypoglycemia (<70mg/dL) From Day 150 to Day 180

The results show an analysis of covariance (ANCOVA) comparing the percentage of time participants in each treatment arm of Cohorts 1 and 2 spent in hypoglycemia with a blood glucose level \<70 mg/dL between the Day 150 and Day 180 visits, based on the total duration of time with available CGM data (i.e., excluding temporary discontinuations). The statistical model included the randomization arm and center (and diabetes type for Cohort 1) as fixed classification effects and the level of hypoglycemia at baseline (i.e. percentage of time spent in hypoglycemia \<70 mg/dL between the Day 0 and Day 30 visits) as baseline covariate. Adjusted means with their 95% confidence intervals are provided.

Time frame:
From Day 150 to Day 180
Reported as:
Mean · Percentage of time
Percentage of Time Spent in Hypoglycemia (<70mg/dL) From Day 150 to Day 180
Percentage of timeCohort 1, Enabled - Eversense XL CGM SystemCohort 1, Control - Usual Glucose Monitoring System (SMBG or FGM)Cohort 2, Enabled - Eversense XL CGM SystemCohort 2, Control - Usual Glucose Monitoring System (SMBG or FGM)
Percentage of Time Spent in Hypoglycemia (<70mg/dL) From Day 150 to Day 1802.1 (0.9 to 3.2)2.4 (1.1 to 3.8)8.4 (6.3 to 10.5)11.7 (8.8 to 14.5)
Statistical analysis
  • Cohort 1, Enabled - Eversense XL CGM System vs Cohort 1, Control - Usual Glucose Monitoring System (SMBG or FGM) · ANCOVA · p = 0.549 (The significance level was set to p\<0.05 (two-sided).) · Mean difference (net): -0.4 · 95% CI -1.5 to 0.8The mean difference was calculated as the Enabled group minus the Control group.
  • Cohort 2, Enabled - Eversense XL CGM System vs Cohort 2, Control - Usual Glucose Monitoring System (SMBG or FGM) · ANCOVA · p = 0.03180 (The significance level was set to p\<0.05 (two-sided).) · Mean difference (net): -3.3 · 95% CI -6.3 to -0.3The mean difference was calculated as the Enabled group minus the Control group.
SecondaryPercentage of Time Spent in Hypoglycemia (<54mg/dL) From Day 150 to Day 180

The results show an analysis of covariance (ANCOVA) comparing the percentage of time participants in each treatment arm of Cohorts 1 and 2 spent in hypoglycemia with a blood glucose level \<54 mg/dL between the Day 150 and Day 180 visits, based on the total duration of time with available CGM data (i.e., excluding temporary discontinuations). The statistical model included the randomization arm and center (and diabetes type for Cohort 1) as fixed classification effects and the level of hypoglycemia at baseline (i.e. percentage of time spent in hypoglycemia \<54 mg/dL between the Day 0 and Day 30 visits) as baseline covariate. Adjusted means with their 95% confidence intervals are provided.

Time frame:
From Day 150 to Day 180
Reported as:
Mean · Percentage of time
Percentage of Time Spent in Hypoglycemia (<54mg/dL) From Day 150 to Day 180
Percentage of timeCohort 1, Enabled - Eversense XL CGM SystemCohort 1, Control - Usual Glucose Monitoring System (SMBG or FGM)Cohort 2, Enabled - Eversense XL CGM SystemCohort 2, Control - Usual Glucose Monitoring System (SMBG or FGM)
Percentage of Time Spent in Hypoglycemia (<54mg/dL) From Day 150 to Day 1801.1 (0.4 to 1.7)1.0 (0.3 to 1.8)3.4 (2.1 to 4.8)6.0 (4.1 to 7.9)
Statistical analysis
  • Cohort 1, Enabled - Eversense XL CGM System vs Cohort 1, Control - Usual Glucose Monitoring System (SMBG or FGM) · ANCOVA · p = 0.859 (The significance level was set to p\<0.05 (two-sided).) · Mean difference (net): 0.1 · 95% CI -0.6 to 0.7The mean difference was calculated as the Enabled group minus the Control group.
  • Cohort 2, Enabled - Eversense XL CGM System vs Cohort 2, Control - Usual Glucose Monitoring System (SMBG or FGM) · ANCOVA · p = 0.01124 (The significance level was set to p\<0.05 (two-sided).) · Mean difference (net): -2.6 · 95% CI -4.5 to -0.6The mean difference was calculated as the Enabled group minus the Control group.
SecondaryCohort 2, Enabled Arm: Percentage of Time Spent in Hypoglycemia (<54 mg/dL) During the Day 90-120 Period Compared With the Day 150-180 Period for the Enabled Group

The results show an analysis of covariance (ANCOVA) comparing the percentage of time participants in the Enabled arm of Cohort 2 spent in hypoglycemia with a blood glucose level \<54 mg/dL over two different time periods (between the Days 90-120 and Days 150-180), based on the total duration of time with available CGM data (i.e., excluding temporary discontinuations). The statistical model included the time period and center as fixed classification effects and the level of hypoglycemia at baseline (i.e. percentage of time spent in hypoglycemia \<54 mg/dL between the Day 0 and Day 30 visits) as baseline covariate. Adjusted means with their 95% confidence intervals are provided.

Time frame:
Day 90 to Day 120; Day 150 to Day 180
Reported as:
Mean · Percentage of time
Cohort 2, Enabled Arm: Percentage of Time Spent in Hypoglycemia (<54 mg/dL) During the Day 90-120 Period Compared With the Day 150-180 Period for the Enabled Group
Percentage of timeCohort 2, Enabled (Day 90 to 120) - Eversense XL CGM SystemCohort 2, Enabled (Day 150 to 180) - Eversense XL CGM System
Cohort 2, Enabled Arm: Percentage of Time Spent in Hypoglycemia (<54 mg/dL) During the Day 90-120 Period Compared With the Day 150-180 Period for the Enabled Group4.232 (3.242 to 5.222)3.430 (2.469 to 4.391)
Statistical analysis
  • Cohort 2, Enabled (Day 90 to 120) - Eversense XL CGM System vs Cohort 2, Enabled (Day 150 to 180) - Eversense XL CGM System · Mixed Models Analysis · p = 0.045 (The significance level was set to p\<0.05 (two-sided).) · Mean difference (net): -0.802 · 95% CI -1.1585 to -0.018The mean difference was calculated as the Enabled (D150-180) group minus the Enabled (D90-120) group.
SecondaryCohort 2, Control Arm: Percentage of Time Spent in Hypoglycemia (<54 mg/dL) During the Control Period (Days 90-120) Compared With the Enabled Period (Days 150-180) for Participants Who Switched to Use the CGM System

The results show an analysis of covariance (ANCOVA) comparing the percentage of time participants in the Cohort 2, Control arm spent in hypoglycemia with a blood glucose level \<54 mg/dL with a different intervention over each of the two time periods (the control period, using their usual glucose monitoring system: Days 90-120, and the enabled period, using the Eversense XL CGM system: Days 150-180), based on the total duration of time with available CGM data (i.e., excluding temporary discontinuations). The statistical model included the time period and center as fixed classification effects and the level of hypoglycemia at baseline (i.e. percentage of time spent in hypoglycemia \<54 mg/dL between the Day 0 and Day 30 visits) as baseline covariate. Adjusted means with their 95% confidence intervals are provided.

Time frame:
For Cohort 2, Control arm: Day 90 to Day 120; For Cohort 2, Switch from Control to Enabled arm: Day 150 to Day 180
Reported as:
Mean · Percentage of time
Cohort 2, Control Arm: Percentage of Time Spent in Hypoglycemia (<54 mg/dL) During the Control Period (Days 90-120) Compared With the Enabled Period (Days 150-180) for Participants Who Switched to Use the CGM System
Percentage of timeCohort 2, Control (Day 90 to 120) - Usual Glucose Monitoring System (SMBG or FGM)Cohort 2, Switch From Control to Enabled (Day 150 to 180) - Eversense XL CGM System
Cohort 2, Control Arm: Percentage of Time Spent in Hypoglycemia (<54 mg/dL) During the Control Period (Days 90-120) Compared With the Enabled Period (Days 150-180) for Participants Who Switched to Use the CGM System5.792 (3.672 to 7.913)6.263 (2.737 to 9.788)
Statistical analysis
  • Cohort 2, Control (Day 90 to 120) - Usual Glucose Monitoring System (SMBG or FGM) vs Cohort 2, Switch From Control to Enabled (Day 150 to 180) - Eversense XL CGM System · Mixed Model for Repeated Measures · p = 0.763 (The significance level was set to p\<0.05 (two-sided).) · Mean difference (net): 0.470 · 95% CI -2.741 to 3.682The mean difference was calculated as the Switch to Enabled (D150-180) group minus the Control (D90-120) group.
SecondaryGlucose Variability From Day 90 to Day 120, as Estimated With a Coefficient of Variation

Glucose variability was estimated with a unitless coefficient of variation, expressed as a percentage, which was computed using CGM data with the following formula: the sum of the ratios of standard deviation of daily glycemia to the mean of daily glycemia divided by the number of days with available data for the period of interest (Days 90 to 120). According to Monnier et al. Diabetes Care 2017, a coefficient of variation threshold set to 36% allows to distinguish between stable and unstable glycemia.

Time frame:
From Day 90 to Day 120
Reported as:
Mean · Coefficient of variation (%)
Glucose Variability From Day 90 to Day 120, as Estimated With a Coefficient of Variation
Coefficient of variation (%)Cohort 1, Enabled - Eversense XL CGM SystemCohort 1, Control - Usual Glucose Monitoring System (SMBG or FGM)Cohort 2, Enabled - Eversense XL CGM SystemCohort 2, Control - Usual Glucose Monitoring System (SMBG or FGM)
Glucose Variability From Day 90 to Day 120, as Estimated With a Coefficient of Variation29.3 (27.5 to 31.1)28.0 (26.0 to 30.0)35.8 (34.3 to 37.3)36.3 (34.3 to 38.3)
Statistical analysis
  • Cohort 1, Enabled - Eversense XL CGM System vs Cohort 1, Control - Usual Glucose Monitoring System (SMBG or FGM) · ANCOVA · p = 0.140 (The significance level was set to p\<0.05 (two-sided).) · Mean difference (net): 1.3 · 95% CI -0.4 to 3.0The mean difference was calculated as the Enabled group minus the Control group.
  • Cohort 2, Enabled - Eversense XL CGM System vs Cohort 2, Control - Usual Glucose Monitoring System (SMBG or FGM) · ANCOVA · p = 0.64110 (The significance level was set to p\<0.05 (two-sided).) · Mean difference (net): -0.5 · 95% CI -2.6 to 1.6The mean difference was calculated as the Enabled group minus the Control group.
SecondaryGlucose Variability From Day 150 to Day 180, as Estimated by a Coefficient of Variation

Glucose variability was estimated with a unitless coefficient of variation, expressed as a percentage, which was computed using CGM data with the following formula: the sum of the ratios of standard deviation of daily glycemia to the mean of daily glycemia divided by the number of days with available data for the period of interest (Days 150 to 180). According to Monnier et al. Diabetes Care 2017, a coefficient of variation threshold set to 36% allows to distinguish between stable and unstable glycemia.

Time frame:
From Day 150 to Day 180
Reported as:
Mean · Coefficient of variation (%)
Glucose Variability From Day 150 to Day 180, as Estimated by a Coefficient of Variation
Coefficient of variation (%)Cohort 1, Enabled - Eversense XL CGM SystemCohort 1, Control - Usual Glucose Monitoring System (SMBG or FGM)Cohort 2, Enabled - Eversense XL CGM SystemCohort 2, Control - Usual Glucose Monitoring System (SMBG or FGM)
Glucose Variability From Day 150 to Day 180, as Estimated by a Coefficient of Variation26.0 (23.9 to 28.1)25.0 (22.6 to 27.5)34.4 (32.8 to 36.0)35.1 (32.8 to 37.3)
Statistical analysis
  • Cohort 1, Enabled - Eversense XL CGM System vs Cohort 1, Control - Usual Glucose Monitoring System (SMBG or FGM) · ANCOVA · p = 0.339 (The significance level was set to p\<0.05 (two-sided).) · Mean difference (net): 1.0 · 95% CI -1.1 to 3.1The mean difference was calculated as the Enabled group minus the Control group.
  • Cohort 2, Enabled - Eversense XL CGM System vs Cohort 2, Control - Usual Glucose Monitoring System (SMBG or FGM) · ANCOVA · p = 0.57677 (The significance level was set to p\<0.05 (two-sided).) · Mean difference (net): -0.7 · 95% CI -3.0 to 1.7The mean difference was calculated as the Enabled group minus the Control group.
SecondaryHbA1c (%) Levels at Day 120

The results show an analysis of covariance (ANCOVA) comparing the HbA1c (%), defined as the percentage of hemoglobin proteins that are glycated (i.e., chemically linked to a sugar), at the Day 120 visit between the Enabled and Control arms for Cohorts 1 and 2. The statistical model included the randomization arm and center (and diabetes type for Cohort 1) as fixed classification effects, and HbA1c (%) at Day 0 as baseline covariates. Adjusted means with their 95% confidence interval are provided.

Time frame:
Day 120
Reported as:
Mean · HbA1c (%)
HbA1c (%) Levels at Day 120
HbA1c (%)Cohort 1, Enabled - Eversense XL CGM SystemCohort 1, Control - Usual Glucose Monitoring System (SMBG or FGM)Cohort 2, Enabled - Eversense XL CGM SystemCohort 2, Control - Usual Glucose Monitoring System (SMBG or FGM)
HbA1c (%) Levels at Day 1208.6 (8.4 to 8.9)8.7 (8.4 to 9.0)7.2 (7.0 to 7.3)7.3 (7.0 to 7.5)
Statistical analysis
  • Cohort 1, Enabled - Eversense XL CGM System vs Cohort 1, Control - Usual Glucose Monitoring System (SMBG or FGM) · ANCOVA · p = 0.558 (The significance level was set to p\<0.05 (two-sided).) · Mean difference (net): -0.1 · 95% CI -0.3 to 0.2The mean difference was calculated as the Enabled group minus the Control group.
  • Cohort 2, Enabled - Eversense XL CGM System vs Cohort 2, Control - Usual Glucose Monitoring System (SMBG or FGM) · ANCOVA · p = 0.408 (The significance level was set to p\<0.05 (two-sided).) · Mean difference (net): -0.1 · 95% CI -0.3 to 0.1The mean difference was calculated as the Enabled group minus the Control group.
SecondaryCohort 2: HbA1c (%) Levels at Day 180

The analysis of this secondary outcome measure for Cohort 2 was an analysis of covariance (ANCOVA) comparing the HbA1c (%), defined as the percentage of hemoglobin proteins that are glycated (i.e., chemically linked to a sugar), at the Day 180 visit between the Enabled and Control arms. The statistical model included the randomization arm and center as fixed classification effects, and HbA1c (%) at Day 0 as baseline covariates. Adjusted means with their 95% confidence interval are provided.

Time frame:
Day 180
Reported as:
Mean · HbA1c (%)
Cohort 2: HbA1c (%) Levels at Day 180
HbA1c (%)Cohort 2, Enabled - Eversense XL CGM SystemCohort 2, Control - Usual Glucose Monitoring System (SMBG or FGM)
Cohort 2: HbA1c (%) Levels at Day 1807.2 (7.0 to 7.4)7.2 (6.9 to 7.4)
Statistical analysis
  • Cohort 2, Enabled - Eversense XL CGM System vs Cohort 2, Control - Usual Glucose Monitoring System (SMBG or FGM) · ANCOVA · p = 0.616 (The significance level was set to p\<0.05 (two-sided).) · Mean difference (net): 0.1 · 95% CI -0.2 to 0.4The mean difference in HbA1c (%) at Day 180 was calculated as the Enabled group minus the Control group.
SecondaryNumber of Participants With the First Sensor Operating at Day 150 and Day 180

This measure assesses sensor life by counting the number of participants with their first inserted CGM sensor still operating at 150 days and at 180 days post-insertion. The assessment was based on the lifespan of the first sensor: for example, if lifespan of the first sensor was ≥150 days and ≥180 days, then the participant was counted as having their first sensor operating at 150 days and 180 days, respectively. The lifespan of the first inserted CGM sensor for each participant, measured in days, was calculated as the date of the last glucose measurement by the sensor minus the date of the first glucose measurement by the sensor (+1 day).

Time frame:
From Day 0 up to Day 150 and Day 180
Reported as:
Count of participants · Participants
Number of Participants With the First Sensor Operating at Day 150 and Day 180
ParticipantsCohort 1, Enabled - Eversense XL CGM SystemCohort 1, Control - Usual Glucose Monitoring System (SMBG or FGM)Cohort 2, Enabled - Eversense XL CGM SystemCohort 2, Control - Usual Glucose Monitoring System (SMBG or FGM)
Day 15073274019
Day 18038102712
SecondaryMean Lifespan of the First Sensor

The lifespan of the first inserted CGM sensor for each participant, measured in days, was calculated as the date of the last glucose measurement by the sensor minus the date of the first glucose measurement by the sensor (+1 day).

Time frame:
From Day 0 up to Day 180
Reported as:
Mean · Days
Mean Lifespan of the First Sensor
DaysCohort 1, Enabled - Eversense XL CGM SystemCohort 1, Control - Usual Glucose Monitoring System (SMBG or FGM)Cohort 2, Enabled - Eversense XL CGM SystemCohort 2, Control - Usual Glucose Monitoring System (SMBG or FGM)
Mean Lifespan of the First Sensor159.2 ± 33.0139.8 ± 46.3147.3 ± 47.8156.9 ± 33.2
SecondaryMedian Number of Sensors Used by Each Participant During the Study
Time frame:
From Day 0 to Day 180
Reported as:
Median · Sensors per participant
Median Number of Sensors Used by Each Participant During the Study
Sensors per participantCohort 1, Enabled - Eversense XL CGM SystemCohort 1, Control - Usual Glucose Monitoring System (SMBG or FGM)Cohort 2, Enabled - Eversense XL CGM SystemCohort 2, Control - Usual Glucose Monitoring System (SMBG or FGM)
Median Number of Sensors Used by Each Participant During the Study1.0 (1.0 to 2.0)1.0 (1.0 to 2.0)1.0 (1.0 to 2.0)1.0 (1.0 to 2.0)
SecondaryNumber of Participants With the First Transmitter Operating at Day 150 and Day 180

This measure assesses transmitter wear time by counting the number of participants with their first CGM transmitter still operating at 150 days and at 180 days after first use. The assessment was based on the lifespan of the first transmitter: for example, if lifespan of the first transmitter was ≥150 days and ≥180 days, then the participant was counted as having their first transmitter operating at 150 days and 180 days, respectively. The lifespan of the first CGM transmitter for each participant, measured in days, was calculated as the date of the last glucose measurement with the transmitter minus the date of the first glucose measurement with the transmitter (+1 day).

Time frame:
From Day 0 up to Day 150 and Day 180
Reported as:
Count of participants · Participants
Number of Participants With the First Transmitter Operating at Day 150 and Day 180
ParticipantsCohort 1, Enabled - Eversense XL CGM SystemCohort 1, Control - Usual Glucose Monitoring System (SMBG or FGM)Cohort 2, Enabled - Eversense XL CGM SystemCohort 2, Control - Usual Glucose Monitoring System (SMBG or FGM)
Day 15012303
Day 18011303
SecondaryMean Lifespan of the First Transmitter

The lifespan of the first CGM transmitter for each participant, measured in days, was calculated as the date of the last glucose measurement with the transmitter minus the date of the first glucose measurement with the transmitter (+1 day).

Time frame:
From Day 0 up to Day 180
Reported as:
Mean · Days
Mean Lifespan of the First Transmitter
DaysCohort 1, Enabled - Eversense XL CGM SystemCohort 1, Control - Usual Glucose Monitoring System (SMBG or FGM)Cohort 2, Enabled - Eversense XL CGM SystemCohort 2, Control - Usual Glucose Monitoring System (SMBG or FGM)
Mean Lifespan of the First Transmitter34.6 ± 19.2140.6 ± 46.533.8 ± 12.4114.6 ± 39.2
SecondaryMedian Number of Transmitters Used by Each Participant During the Study
Time frame:
From Day 0 to Day 180
Reported as:
Median · Transmitters per participant
Median Number of Transmitters Used by Each Participant During the Study
Transmitters per participantCohort 1, Enabled - Eversense XL CGM SystemCohort 1, Control - Usual Glucose Monitoring System (SMBG or FGM)Cohort 2, Enabled - Eversense XL CGM SystemCohort 2, Control - Usual Glucose Monitoring System (SMBG or FGM)
Median Number of Transmitters Used by Each Participant During the Study2.0 (1.0 to 4.0)1.0 (1.0 to 2.0)2.0 (1.0 to 3.0)2.0 (1.0 to 4.0)
SecondaryNumber of Participants Who Accessed CGM Application Pages at Days 60, 120, and 180

This was a descriptive analysis of the number of participants in the Eversense XL CGM System Enabled groups who accessed the various CGM application (app) pages/functions at study Days 60, 120, and 180. The data were collected in the electronic Case Report Form.

Time frame:
At Days 60, 120, and 180
Reported as:
Count of participants · Participants
Number of Participants Who Accessed CGM Application Pages at Days 60, 120, and 180
ParticipantsCohort 1, Enabled - Eversense XL CGM SystemCohort 2, Enabled - Eversense XL CGM System
Day 60 - Participant uses the 'Report' function6743
Day 60 - Participant uses the 'Historic of Alerts' function7544
Day 60 - Participant uses the 'Log Event' function6138
Day 60 - Participant uses phone to look at their glucose levels9561
Day 120 - Participant uses the 'Report' function6650
Day 120 - Participant uses the 'Historic of Alerts' function7440
Day 120 - Participant uses the 'Log Event' function6328
Day 120 - Participant uses phone to look at their glucose levels8958
Day 180 - Participant uses the 'Report' function5849
Day 180 - Participant uses the 'Historic of Alerts' function6146
Day 180 - Participant uses the 'Log Event' function5435
Day 180 - Participant uses phone to look at their glucose levels8155
SecondaryNumber of Participants Issued at Least One Type of Alarm or Alert by the CGM System During the Study

This outcome measure is a descriptive analysis of the number of participants who were issued various types of alarms and alerts by the Eversense XL CGM System through the mobile medical application. The alarms listed in the results table are a higher level classification for the different types of alerts that immediately follow it, until the next type of alarm is listed (for example, the 'Calibration' alarm included both 'Calibrate Now' and 'Calibration Past Due' alerts). Only participants in the Enabled groups of both cohorts actually received these alarms/alerts because the CGM remained in blinded mode for participants in the Control groups.

Time frame:
From Day 0 up to Day 180
Reported as:
Count of participants · Participants
Number of Participants Issued at Least One Type of Alarm or Alert by the CGM System During the Study
ParticipantsCohort 1, Enabled - Eversense XL CGM SystemCohort 1, Control - Usual Glucose Monitoring System (SMBG or FGM)Cohort 2, Enabled - Eversense XL CGM SystemCohort 2, Control - Usual Glucose Monitoring System (SMBG or FGM)
At Least 1 Alarm of Any Type97526228
At Least 1 'Calibration' Alarm97526228
At Least 1 'Calibrate Now' Alert97526228
At Least 1 'Calibration Past Due' Alert95506126
At Least 1 'Sensor Glucose' Alarm9526122
At Least 1 'High Glucose' Alert9526122
At Least 1 'Low Glucose' Alert9426122
At Least 1 'Out of Range High Glucose' Alert861478
At Least 1 'Out of Range Low Glucose' Alert8426122
At Least 1 'Predicted High Glucose' Alert441398
At Least 1 'Predicted Low Glucose' Alert441388
At Least 1 'Rate Falling' Alert311276
At Least 1 'Rate Rising' Alert311276
At Least 1 'Sensor Glucose and Calibration' Alarm31191810
At Least 1 'Sensor Check' Alert31191810
At Least 1 'Sensor Related' Alarm97526228
At Least 1 'High Ambient Light Alert' Alert84404719
At Least 1 'High Sensor Temperature' Alert1130
At Least 1 'Low Sensor Temperature' Alert7444
At Least 1 'New Sensor Detected' Alert95516228
At Least 1 'Sensor Replacement' Alert93465827
At Least 1 'System Related' Alarm, 'Displayed on the Status Bar of the App' Alert97526228
At Least 1 'Transmitter Related' Alarm97526228
At Least 1 'Battery Empty' Alert82445721
At Least 1 'Charge Transmitter' Alert94495928
At Least 1 'High Transmitter Temperature' Alert2111164
At Least 1 'Transmitter Disconnect' Alert97526228
At Least 1 'Transmitter Error' Alert9263
SecondaryDiabetes Treatment Satisfaction Questionnaire - Original Status (DTSQs) Treatment Satisfaction Score at Baseline, Day 60, and Day 180

The DTSQs questionnaire contains eight items scored on a 7-point scale (i.e. each item is scored from 0 to 6). Six items measure Treatment Satisfaction, dealing with: satisfaction with current treatment; convenience of the treatment; flexibility; satisfaction with own understanding of participant's diabetes; how likely to recommend their present treatment; and how satisfied to continue with their present treatment. These are summed to produce a total Treatment Satisfaction score, with a minimum value of 0 and a maximum value of 36; a higher score indicates greater treatment satisfaction. In case of missing items, the overall score was calculated as the mean of the available items.

Time frame:
Baseline (Day 0), Day 60, and Day 180
Reported as:
Mean · Score on a scale
Diabetes Treatment Satisfaction Questionnaire - Original Status (DTSQs) Treatment Satisfaction Score at Baseline, Day 60, and Day 180
Score on a scaleCohort 1, Enabled - Eversense XL CGM SystemCohort 1, Control - Usual Glucose Monitoring System (SMBG or FGM)Cohort 2, Enabled - Eversense XL CGM SystemCohort 2, Control - Usual Glucose Monitoring System (SMBG or FGM)
Baseline27.0 ± 6.024.4 ± 6.326.4 ± 5.426.8 ± 5.7
Day 6028.3 ± 5.824.3 ± 5.927.9 ± 4.924.4 ± 6.1
Day 18026.8 ± 6.424.5 ± 7.127.6 ± 4.226.2 ± 6.1
SecondaryChange From Baseline in the DTSQs Treatment Satisfaction Score at Day 60 and Day 180

The DTSQs questionnaire contains eight items scored on a 7-point scale (i.e. each item is scored from 0 to 6). Six items measure Treatment Satisfaction (dealing with: satisfaction with current treatment; convenience of the treatment; flexibility; satisfaction with own understanding of participant's diabetes; how likely to recommend their present treatment; and how satisfied to continue with their present treatment). These are summed to produce a total Treatment Satisfaction score, with a minimum value of 0 and a maximum value of 36; a higher score indicates greater treatment satisfaction. For the change from baseline analysis, a positive value indicates an improvement in treatment satisfaction. In case of missing items, the overall score was calculated as the mean of the available items.

Time frame:
Baseline (Day 0), Day 60, and Day 180
Reported as:
Mean · Score on a scale
Change From Baseline in the DTSQs Treatment Satisfaction Score at Day 60 and Day 180
Score on a scaleCohort 1, Enabled - Eversense XL CGM SystemCohort 1, Control - Usual Glucose Monitoring System (SMBG or FGM)Cohort 2, Enabled - Eversense XL CGM SystemCohort 2, Control - Usual Glucose Monitoring System (SMBG or FGM)
Change from Baseline at Day 601.3 ± 5.10.2 ± 6.31.7 ± 5.5-1.8 ± 4.1
Change from Baseline at Day 180-0.1 ± 6.4-0.1 ± 6.61.3 ± 4.4-0.1 ± 4.8
SecondaryDiabetes Treatment Satisfaction Questionnaire - Change Version (DTSQc) Treatment Satisfaction Score at Day 180

The DTSQc questionnaire contains eight items scored on a 7-point scale (i.e. each item is scored from -3 to +3). Six items measure Treatment Satisfaction (dealing with: satisfaction with current treatment; convenience of the treatment; flexibility; satisfaction with own understanding of participant's diabetes; how likely to recommend their present treatment; and how satisfied to continue with their present treatment). These are summed to produce a total Treatment Satisfaction score, with a minimum value of -18 and a maximum value of +18; a higher score indicates greater treatment satisfaction. In case of missing items, the overall score was calculated as the mean of the available items.

Time frame:
Day 180
Reported as:
Mean · Score on a scale
Diabetes Treatment Satisfaction Questionnaire - Change Version (DTSQc) Treatment Satisfaction Score at Day 180
Score on a scaleCohort 1, Enabled - Eversense XL CGM SystemCohort 1, Control - Usual Glucose Monitoring System (SMBG or FGM)Cohort 2, Enabled - Eversense XL CGM SystemCohort 2, Control - Usual Glucose Monitoring System (SMBG or FGM)
Diabetes Treatment Satisfaction Questionnaire - Change Version (DTSQc) Treatment Satisfaction Score at Day 1808.6 ± 7.87.1 ± 7.08.6 ± 6.65.3 ± 8.7
SecondaryAudit of Diabetes-Dependent Quality of Life (ADDQoL) Score at Baseline and Day 180

The ADDQoL measures the impact of diabetes and its treatment on 19 specific aspects of life. The scale ranges from -3 to +1 for 19 life domains (impact rating) and from 0 to +3 in attributed importance (importance rating). A weighted score for each domain is calculated as a multiplier of impact rating and importance rating (ranging from -9 to +3). Finally, a mean weighted impact score (ADDQOL score) is calculated for the entire scale across all applicable domains; a higher score indicates greater quality of life.

Time frame:
Baseline (Day 0) and Day 180
Reported as:
Mean · Score on a scale
Audit of Diabetes-Dependent Quality of Life (ADDQoL) Score at Baseline and Day 180
Score on a scaleCohort 1, Enabled - Eversense XL CGM SystemCohort 1, Control - Usual Glucose Monitoring System (SMBG or FGM)Cohort 2, Enabled - Eversense XL CGM SystemCohort 2, Control - Usual Glucose Monitoring System (SMBG or FGM)
Baseline-2.9 ± 1.9-3.0 ± 1.6-2.7 ± 1.9-1.9 ± 1.4
Day 180-2.7 ± 1.9-3.2 ± 2.1-2.5 ± 1.7-1.4 ± 1.2
SecondaryChange From Baseline in the Audit of Diabetes-Dependent Quality of Life (ADDQoL) Score at Day 180

The ADDQoL measures the impact of diabetes and its treatment on 19 specific aspects of life. The scale ranges from -3 to +1 for 19 life domains (impact rating) and from 0 to +3 in attributed importance (importance rating). A weighted score for each domain is calculated as a multiplier of impact rating and importance rating (ranging from -9 to +3). Finally, a mean weighted impact score (ADDQOL score) is calculated for the entire scale across all applicable domains; a higher score indicates greater quality of life. For the change from baseline analysis, a positive value indicates an improvement in quality of life.

Time frame:
Baseline (Day 0) and Day 180
Reported as:
Mean · Score on a scale
Change From Baseline in the Audit of Diabetes-Dependent Quality of Life (ADDQoL) Score at Day 180
Score on a scaleCohort 1, Enabled - Eversense XL CGM SystemCohort 1, Control - Usual Glucose Monitoring System (SMBG or FGM)Cohort 2, Enabled - Eversense XL CGM SystemCohort 2, Control - Usual Glucose Monitoring System (SMBG or FGM)
Change From Baseline in the Audit of Diabetes-Dependent Quality of Life (ADDQoL) Score at Day 1800.1 ± 1.40.0 ± 1.00.1 ± 1.10.4 ± 1.2
SecondaryThe Continuous Glucose Monitoring Satisfaction (CGM-SAT) Questionnaire Overall Score at Day 60 and Day 180

The CGM-SAT questionnaire comprises 44 item scales assessing experiences with CGM over the previous 6 months. The scale is designed to measure the impact of CGM on diabetes management and family relationships, plus on satisfaction with emotional, behavioral and cognitive effects of CGM use. The responses were rated on a 5-point scale from '1 = strongly agree' to '5 = strongly disagree'. The overall score corresponds to the mean of the 44 items of potential positive or negative effects of using the CGM device; a higher score reflects more favorable impact of, and satisfaction with CGM. In case of missing items, the overall score was calculated as the mean of the available items.

Time frame:
Day 60 and Day 180
Reported as:
Mean · Score on a scale
The Continuous Glucose Monitoring Satisfaction (CGM-SAT) Questionnaire Overall Score at Day 60 and Day 180
Score on a scaleCohort 1, Enabled - Eversense XL CGM SystemCohort 2, Enabled - Eversense XL CGM System
Day 602.9 ± 0.33.0 ± 0.3
Day 1802.8 ± 0.32.8 ± 0.3
SecondaryChange From Day 60 in the CGM-SAT Questionnaire Overall Score at Day 180

The CGM-SAT questionnaire comprises 44 item scales assessing experiences with CGM over the previous 6 months. The scale is designed to measure the impact of CGM on diabetes management and family relationships, plus on satisfaction with emotional, behavioral and cognitive effects of CGM use. The responses were rated on a 5-point scale from '1 = strongly agree' to '5 = strongly disagree'. The overall score corresponds to the mean of the 44 items of potential positive or negative effects of using the CGM device; a higher score (or positive change from baseline score) reflects more favorable impact of, and satisfaction with CGM. In case of missing items, the overall score was calculated as the mean of the available items.

Time frame:
Day 60 and Day 180
Reported as:
Mean · Score on a scale
Change From Day 60 in the CGM-SAT Questionnaire Overall Score at Day 180
Score on a scaleCohort 1, Enabled - Eversense XL CGM SystemCohort 2, Enabled - Eversense XL CGM System
Change From Day 60 in the CGM-SAT Questionnaire Overall Score at Day 180-0.1 ± 0.3-0.1 ± 0.2
SecondaryDiabetes Distress Scale 2 (DDS2) Questionnaire Score at Baseline, Day 60, and Day 180

The DDS2 is a 2-item diabetes distress screening instrument asking respondents to rate on a 6-point scale (from 1 = 'Not a problem' to 6 = 'A very serious problem') the degree to which the following items caused distress: (1) feeling overwhelmed by the demands of living with diabetes, and (2) feeling that I am often failing with my diabetes regimen. The DDS2 score is the mean of the two items (ranging from 1 to 6). A lower DDS2 score (or a negative change from baseline score) indicates a lower level of distress. If one item was missing, then no score was computed.

Time frame:
Baseline (Day 0), Day 60, and Day 180
Reported as:
Mean · Score on a scale
Diabetes Distress Scale 2 (DDS2) Questionnaire Score at Baseline, Day 60, and Day 180
Score on a scaleCohort 1, Enabled - Eversense XL CGM SystemCohort 1, Control - Usual Glucose Monitoring System (SMBG or FGM)Cohort 2, Enabled - Eversense XL CGM SystemCohort 2, Control - Usual Glucose Monitoring System (SMBG or FGM)
Baseline2.4 ± 1.13.1 ± 1.62.8 ± 1.22.3 ± 1.0
Day 602.1 ± 1.03.0 ± 1.22.6 ± 1.53.0 ± 2.0
Day 1802.1 ± 1.22.6 ± 1.12.4 ± 1.32.0 ± 1.1
SecondaryChange From Baseline in the Diabetes Distress Scale 2 (DDS2) Questionnaire Score at Day 60 and Day 180

The DDS2 is a 2-item diabetes distress screening instrument asking respondents to rate on a 6-point scale (from 1 = 'Not a problem' to 6 = 'A very serious problem') the degree to which the following items caused distress: (1) feeling overwhelmed by the demands of living with diabetes, and (2) feeling that I am often failing with my diabetes regimen. The DDS2 score is the mean of the two items (ranging from 1 to 6). A lower DDS2 score (or a negative change from baseline score) indicates a lower level of distress. If one item was missing, then no score was computed.

Time frame:
Baseline (Day 0), Day 60, and Day 180
Reported as:
Mean · Score on a scale
Change From Baseline in the Diabetes Distress Scale 2 (DDS2) Questionnaire Score at Day 60 and Day 180
Score on a scaleCohort 1, Enabled - Eversense XL CGM SystemCohort 1, Control - Usual Glucose Monitoring System (SMBG or FGM)Cohort 2, Enabled - Eversense XL CGM SystemCohort 2, Control - Usual Glucose Monitoring System (SMBG or FGM)
Change from Baseline at Day 60-0.2 ± 0.80.0 ± 1.2-0.3 ± 2.10.6 ± 1.4
Change from Baseline at Day 180-0.2 ± 0.9-0.6 ± 1.5-0.5 ± 1.90.0 ± 0.8
SecondaryHypoglycemia Fear Survey, Part 2 (HFS2) Worry Subscale Score at Baseline, Day 60, and Day 180

HFS2 Worry items describe specific concerns that patients may have about their hypoglycemic episodes (e.g., being alone, episodes occurring during sleep, or having an accident). The 5-point Likert scale for each item ranges from 0 (never) to 4 (almost always), and the HFS2 Worry subscale score is the sum of all 18 items (ranging from 0 to 72). A lower HFS2 Worry subscale score (or a negative change from baseline score) indicates a lower level of fear of hypoglycemia. There was no plan to replace missing items: if one item was missing, the score was not computed.

Time frame:
Baseline (Day 0), Day 60, and Day 180
Reported as:
Mean · Score on a scale
Hypoglycemia Fear Survey, Part 2 (HFS2) Worry Subscale Score at Baseline, Day 60, and Day 180
Score on a scaleCohort 1, Enabled - Eversense XL CGM SystemCohort 1, Control - Usual Glucose Monitoring System (SMBG or FGM)Cohort 2, Enabled - Eversense XL CGM SystemCohort 2, Control - Usual Glucose Monitoring System (SMBG or FGM)
Baseline21.4 ± 12.021.6 ± 9.426.6 ± 14.419.0 ± 7.9
Day 6017.4 ± 10.721.3 ± 9.727.1 ± 16.218.8 ± 13.8
Day 18015.4 ± 11.324.4 ± 6.228.9 ± 17.014.8 ± 11.4
SecondaryChange From Baseline in the Hypoglycemia Fear Survey, Part 2 (HFS2) Worry Subscale Score at Day 60 and Day 180

HFS2 Worry items describe specific concerns that patients may have about their hypoglycemic episodes (e.g., being alone, episodes occurring during sleep, or having an accident). The 5-point Likert scale for each item ranges from 0 (never) to 4 (almost always), and the HFS2 Worry subscale score is the sum of all 18 items (ranging from 0 to 72). A lower HFS2 Worry subscale score (or a negative change from baseline score) indicates a lower level of fear of hypoglycemia. There was no plan to replace missing items: if one item was missing, the score was not computed.

Time frame:
Baseline (Day 0), Day 60, and Day 180
Reported as:
Mean · Score on a scale
Change From Baseline in the Hypoglycemia Fear Survey, Part 2 (HFS2) Worry Subscale Score at Day 60 and Day 180
Score on a scaleCohort 1, Enabled - Eversense XL CGM SystemCohort 1, Control - Usual Glucose Monitoring System (SMBG or FGM)Cohort 2, Enabled - Eversense XL CGM SystemCohort 2, Control - Usual Glucose Monitoring System (SMBG or FGM)
Change from Baseline at Day 60-4.0 ± 8.7-0.3 ± 6.8-1.4 ± 7.2-1.4 ± 6.2
Change from Baseline at Day 180-5.2 ± 9.81.4 ± 12.50.9 ± 10.1-3.0 ± 4.8
SecondaryChange From Baseline in the Partner Diabetes Distress Scale (Partner-DDS) Questionnaire Total and Subscale Scores at Day 60 and Day 180

The Partner-DDS is a 21-item self-report scale that highlights four critical dimensions of partner-related distress: "my partner's diabetes management", "how best to help", "diabetes and me", and "hypoglycemia". The scale ranges from 0 (not at all) to 4 (a great deal). The Partner-DDS yields a total diabetes distress score plus 4 subscale scores: Total Partner-DDS Score = Mean of the 21 items; My partner's diabetes management = Mean of item 3, 4, 10, 12, 14, 15 and 20; How best to help = Mean of item 2, 6, 7, 11 and 13; Diabetes and me = Mean of items 5, 8, 9, 16 and 21; Hypoglycemia = Mean of items 1, 17, 18 and 19. A lower Partner-DDS score (or a negative change from baseline score) indicates a lower level of distress.

Time frame:
Baseline (Day 0), Day 60, and Day 180
Reported as:
Mean · Score on a scale
Change From Baseline in the Partner Diabetes Distress Scale (Partner-DDS) Questionnaire Total and Subscale Scores at Day 60 and Day 180
Score on a scaleCohort 1, Enabled - Eversense XL CGM SystemCohort 1, Control - Usual Glucose Monitoring System (SMBG or FGM)Cohort 2, Enabled - Eversense XL CGM SystemCohort 2, Control - Usual Glucose Monitoring System (SMBG or FGM)
My Partner's Diabetes Management - Change from Baseline (BL) at Day 600.0 ± 0.40.1 ± 0.70.1 ± 0.3-0.4 ± 0.4
My Partner's Diabetes Management - Change from BL at Day 180-1.1 ± 1.50.6 ± NA-0.3 ± 0.0-0.7 ± 0.2
How Best to Help - Change from BL at Day 60-1.7 ± 1.00.9 ± 0.10.1 ± 0.4-0.2 ± 0.0
How Best to Help - Change from BL at Day 180-0.5 ± 0.41.4 ± NA-0.8 ± 0.3-0.3 ± 0.1
Diabetes and Me - Change from BL at Day 60-0.3 ± 0.70.2 ± 0.30.1 ± 0.4-0.3 ± 0.4
Diabetes and Me - Change from BL at Day 1800.3 ± 0.40.4 ± NA-0.9 ± 0.1-0.5 ± 0.4
Hypoglycemia - Change from BL at Day 60-0.3 ± 0.0-0.1 ± 0.50.1 ± 0.20.5 ± 1.1
Hypoglycemia - Change from BL at Day 1800.6 ± 1.20.0 ± NA0.4 ± 0.9-0.3 ± 0.4
PDDS Score - Change from BL at Day 60-0.5 ± 0.30.3 ± 0.10.1 ± 0.3-0.2 ± 0.2
PDDS Score - Change from BL at Day 180-0.3 ± 0.90.6 ± NA-0.4 ± 0.2-0.5 ± 0.1

Adverse events

Collected over From Day 0 (sensor insertion) until Day 180; for Cohort 2, Contol: From Day 0 to Day 120 and From Day 120 to Day 180. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Cohort 1, Enabled - Eversense XL CGM System0/97 (0%)7/97 (7.2%)2/97 (2.1%)
Cohort 1, Control - Usual Glucose Monitoring System (SMBG or FGM)0/52 (0%)5/52 (9.6%)1/52 (1.9%)
Cohort 2, Enabled - Eversense XL CGM System0/62 (0%)2/62 (3.2%)4/62 (6.5%)
Cohort 2, Control (Day 0 to 120) - Usual Glucose Monitoring System (SMBG or FGM)0/28 (0%)0/28 (0%)1/28 (3.6%)
Cohort 2, Control (Day 120 to 180) - Eversense XL CGM System or Usual Glucose Monitoring System0/28 (0%)0/28 (0%)1/28 (3.6%)
Most frequent serious events
Showing 10 of 13
Most frequent serious events
EventCohort 1, Enabled - Eversense XL CGM SystemCohort 1, Control - Usual Glucose Monitoring System (SMBG or FGM)Cohort 2, Enabled - Eversense XL CGM SystemCohort 2, Control (Day 0 to 120) - Usual Glucose Monitoring System (SMBG or FGM)Cohort 2, Control (Day 120 to 180) - Eversense XL CGM System or Usual Glucose Monitoring System
Diabetes mellitus inadequate controlMetabolism and nutrition disorders2/970/520/620/280/28
Diabetic ketosisMetabolism and nutrition disorders0/971/520/620/280/28
Hypoglycaemic comaNervous system disorders0/971/520/620/280/28
Burnout syndromePsychiatric disorders0/971/520/620/280/28
Acute kidney injuryRenal and urinary disorders0/971/520/620/280/28
Renal failureRenal and urinary disorders0/971/520/620/280/28
AnxietyPsychiatric disorders0/970/521/620/280/28
Diverticulum intestinalGastrointestinal disorders0/970/521/620/280/28
NeuritisNervous system disorders1/970/520/620/280/28
Optic neuritisNervous system disorders1/970/520/620/280/28
Most frequent other events
Most frequent other events
EventCohort 1, Enabled - Eversense XL CGM SystemCohort 1, Control - Usual Glucose Monitoring System (SMBG or FGM)Cohort 2, Enabled - Eversense XL CGM SystemCohort 2, Control (Day 0 to 120) - Usual Glucose Monitoring System (SMBG or FGM)Cohort 2, Control (Day 120 to 180) - Eversense XL CGM System or Usual Glucose Monitoring System
HypoglycaemiaMetabolism and nutrition disorders2/971/524/621/281/28

Baseline characteristics

Age, Continuous
Age, Continuous(Years)Cohort 1, Enabled - Eversense XL CGM SystemCohort 1, Control - Usual Glucose Monitoring System (SMBG or FGM)Cohort 2, Enabled - Eversense XL CGM SystemCohort 2, Control - Usual Glucose Monitoring System (SMBG or FGM)Total
Mean43.7 ± 13.841.1 ± 13.045.1 ± 14.147.7 ± 12.744.0 ± 13.7
Sex: Female, Male
Sex: Female, Male(Participants)Cohort 1, Enabled - Eversense XL CGM SystemCohort 1, Control - Usual Glucose Monitoring System (SMBG or FGM)Cohort 2, Enabled - Eversense XL CGM SystemCohort 2, Control - Usual Glucose Monitoring System (SMBG or FGM)Total
Female5527178107
Male42254520132
Race and Ethnicity Not Collected
Race and Ethnicity Not Collected(Participants)Cohort 1, Enabled - Eversense XL CGM SystemCohort 1, Control - Usual Glucose Monitoring System (SMBG or FGM)Cohort 2, Enabled - Eversense XL CGM SystemCohort 2, Control - Usual Glucose Monitoring System (SMBG or FGM)Total
Count of participants————0
Type of Diabetes
Type of Diabetes(Participants)Cohort 1, Enabled - Eversense XL CGM SystemCohort 1, Control - Usual Glucose Monitoring System (SMBG or FGM)Cohort 2, Enabled - Eversense XL CGM SystemCohort 2, Control - Usual Glucose Monitoring System (SMBG or FGM)Total
Type 1 Diabetes84466228220
Type 2 Diabetes1360019
Hemoglobin A1c (HbA1c, %) Levels at Baseline
Hemoglobin A1c (HbA1c, %) Levels at Baseline(HbA1c (%))Cohort 1, Enabled - Eversense XL CGM SystemCohort 1, Control - Usual Glucose Monitoring System (SMBG or FGM)Cohort 2, Enabled - Eversense XL CGM SystemCohort 2, Control - Usual Glucose Monitoring System (SMBG or FGM)Total
Mean9.0 ± 0.99.1 ± 0.97.3 ± 0.86.9 ± 1.08.3 ± 1.3
Percentage of Time Spent in Hypoglycemia (<54 mg/dL) From Day 0 to Day 30
Percentage of Time Spent in Hypoglycemia (<54 mg/dL) From Day 0 to Day 30(Percentage of time)Cohort 1, Enabled - Eversense XL CGM SystemCohort 1, Control - Usual Glucose Monitoring System (SMBG or FGM)Cohort 2, Enabled - Eversense XL CGM SystemCohort 2, Control - Usual Glucose Monitoring System (SMBG or FGM)Total
Mean1.2 ± 1.81.4 ± 2.44.7 ± 4.05.4 ± 4.52.6 ± 3.0
08

Study locations

20 sites
  • CHU Amiens Picardie
    Amiens, 80054, France
  • CHU Caen Normandie
    Caen, 14033, France
  • CHU Grenoble Alpes
    La Tronche, 38700, France
  • Hopital Hotel Dieu - Creusot
    Le Creusot, 71200, France
  • CHRU de Lille
    Lille, 59037, France
  • APHM - Hopital Sainte-Marguerite
    Marseille, 13274, France
  • CHU de Montpellier
    Montpellier, 34295, France
  • Hopital Caremeau-CHU Nimes
    Nimes, 30900, France
  • Paris Lariboisière
    Paris, 75475, France
  • APHP Groupe Hospitalier Cochin (Paris)
    Paris, 75679, France
  • Centre Hospitalier Lyon Sud
    Pierre Benite, 69310, France
  • CHU de Poitiers
    Poitiers, 86021, France
  • CHU Reims
    Reims Cedex, 51092, France
  • CHU Rouen
    Rouen, 76100, France
  • CHU de Nantes
    St Herblain, 44800, France
  • CHRU de Strasbourg
    Strasbourg, 67091, France
  • CHU de Toulouse
    Toulouse, 31059, France
  • CHU de Nancy
    Vandoeuvre Les Nancy, 54511, France
  • Groupe hospitalier Les Portes du Sud
    Venissieux, 69200, France
  • Institut de diabétologie et Nutrition du Centre
    Vernouillet, 28500, France
09

References and documents

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Feb 2018 to primary completion in Aug 2020, 29 months.

Results were first posted in Sep 2021, 1 year after primary completion.

Of 160 industry-sponsored interventional studies with no phase under Diabetes Mellitus, half reached primary completion within 13 months of starting (the median), counting those still running; a quarter within 4 and three quarters within 26. This study's 29 months is above that.

Counting every sponsor, half of 1,747 studies reached it within 21 months; a quarter within 9 and three quarters within 42.

How these figures are worked out, and which studies are left out of them.

Registered
Feb 2, 2018
First posted
Feb 26, 2018
StartActual
Feb 28, 2018
Primary completionActual
Aug 20, 2020
CompletionActual
Aug 20, 2020
Results first posted
Sep 10, 2021
Last update
Sep 10, 2021
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Sep 10, 2021, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT03445065
Lead sponsor
Hoffmann-La Roche
Collaborators
Roche Diabetes Care
Responsible party
Sponsor
First posted
Feb 26, 2018
Start date
Feb 28, 2018
Primary completion
Aug 20, 2020
Completion
Aug 20, 2020
Results posted
Sep 10, 2021
Last update
Sep 10, 2021

Study contacts

Cecile Berteau
study director · Hoffmann-La Roche

Oversight

FDA-regulated drug
No
FDA-regulated device
Yes
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Aug 2021. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion